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ABSTRACT 
Background:  Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative 
disease in the central nervous system which affects a number of life areas of the afflicted 
individual. Detailed knowledge is required on functioning and health in people with MS 
(PwMS) from a broad and longitudinal perspective. There is also an urgent need to increase 
knowledge about effective methods for alleviating depressive symptoms in PwMS. Aims: 
The overall aim in this thesis was to explore the occurrence of disability, health related 
quality of life (HRQL), use of care and patient satisfaction with care, and to explore the 
importance of different variables to predict the occurrence of disability, HRQL and use of 
care in PwMS in a long-term longitudinal perspective. In addition, the aim was to evaluate 
the feasibility of face-to -face cognitive behavioural therapy (CBT) for alleviating depressive 
symptoms in PwMS. Material and Methods: Study I, II and III were based on a 10-year 
follow-up of a population-based sample of PwMS in Stockholm County (n=166). A total of 
123 PwMS agreed to participate in the 10-year follow-up. Information on disease-specific 
variables, contextual factors, various aspects of disability, HRQL and patient satisfaction with 
care were collected by home visits at baseline and at the 10-year follow-up. Information 
regarding time and cause of death was collected from the National Board of Health and 
Welfare. Information regarding use of care was collected from the Stockholm County 
Council. Recruitment of patients to study IV (n=15) was conducted at the Department of 
Neurology, Karolinska University Hospital.  Inclusion criteria were a definite and informed 
MS-diagnosis and sub-threshold to moderate depressive symptoms. The intervention 
included 15-20 individual sessions with a licensed psychotherapist. Main outcome was 
feasibility of methods and measurements used and depressive symptoms. Follow-ups were 
conducted three weeks and three months after completed intervention. Results: There was no 
change in occurrence of PwMS with cognitive impairment, depressive symptoms or 
restrictions in social/lifestyle activities from baseline to the 10-year follow-up. There was an 
increase in occurrence of PwMS with limitation in manual dexterity, walking ability and 
activities of daily living over time. Overall, HRQL was quite stable over time. The use of care 
over time was extensive, including primary care, hospital outpatient and inpatient care. 
Higher disease severity was an important variable in predicting disability. Low coping 
capacity, depressive symptoms and cognitive impairment were important variables in 
predicting HRQL. Low coping capacity, manual dexterity and progress in disease severity 
were important variables in predicting the use of care. Satisfaction with care was quite stable 
over time. Overall, the methods and measurements used in the pilot feasibility study of face-
to-face CBT were found to be feasible. Conclusion:  Awareness of the psychological 
aspects of the disease needs to increase among care professionals. There is a potential to 
decrease the impact of modifiable factors on HRQL in PwMS as well as meeting the need 
for environmental facilitators aiming at reducing disability. By establishing the PwMS as 
full partners to their care providers in care decisions and implement strategies to coordinate 
care between care providers there is a potential to increase efficacy/outcome of care. Face-
to-face CBT is feasible for use in PwMS.   
SAMMANFATTNING 
Bakgrund: Multipel skleros (MS) är en neuroinflammatorisk och neurodegenerativ sjukdom 
i det centrala nervsystemet som påverkar livet för den drabbade personen på flera sätt. 
Detaljerad kunskap om funktion och hälsa hos personer med MS (PmMS) i ett 
långtidsperspektiv behövs. Det behövs också mer kunskap om effektiva metoder för att 
minska depressiva symtom hos PmMS. Syfte: Det övergripande syftet med avhandlingen var 
att undersöka förekomst av funktionshinder, hälsorelaterad livskvalitet (HRLK), utnyttjande 
av och tillfredställelse med sjukvård, samt att undersöka betydelsen av olika faktorer för att 
predicera förekomst av funktionshinder, HRLK och utnyttjande av vård hos PmMS i ett 
långtidsperspektiv. Ytterligare ett syfte var att utvärdera genomförbarheten av individuell 
kognitiv beteendeterapi (KBT) hos PmMS och depressiva symtom. Metod: Studie I, II och 
III baseras på en 10-årsuppföljning av ett populationsbaserat urval av PmMS i Stockholms 
Län (n=166). Totalt 123 PmMS deltog i 10-årsuppföljningen. Information om 
sjukdomsspecifika variabler, kontextuella faktorer, olika aspekter av funktionshinder, HRLK 
och patienttillfredsställelse med vård samlades in genom hembesök vid baslinjen och vid 10-
årsuppföljningen genom tester och frågeformulär. Information om datum för död och 
dödsorsak samlades in via Socialstyrelsens register. Information om utnyttjande av vård 
samlades in genom registerdata från Stockholms Läns Landsting. Rekrytering av deltagare till 
studie IV (n=15) genomfördes vid Neurologiska kliniken, Karolinska Universitetssjukhuset. 
Inklusionskriterier var en säkerställd och informerad MS diagnos och depressiva symtom 
motsvarande milda till måttliga. Interventionen bestod av 15-20 individuella 
behandlingstillfällen med en legitimerad psykoterapeut. Information om genomförbarhet av 
metoder och mätinstrument samt förändring i depressiva symtom och andra funktionshinder 
samlades in. Uppföljning genomfördes tre veckor och tre månader efter avslutad intervention. 
Resultat: Det var ingen skillnad i förekomst av PmMS med kognitiv funktionsnedsättning, 
depressiva symtom eller med inskränkt delaktighet i sociala/livsstils aktiviteter över tid. Det 
var en ökad förekomst av PmMS med begränsad finmotorik och gångförmåga och med 
aktivitetsbegränsningar i dagligt liv. HRLK var överlag stabil över tid. Utnyttjandet av vård 
under tidsperioden var omfattande och inkluderade primärvård, specialistvård och 
inneliggande sjukhusvård. Högre sjukdomsgrad var en viktig variabel för att predicera 
förekomst av funktionshinder. Låg coping förmåga, depressiva symtom och kognitiv 
funktionsnedsättning var viktiga variabler för att predicera en minskning av HRLK. Låg 
coping förmåga, depressiva symtom, begränsad finmotorik och en ökning av sjukdomsgraden 
var viktiga variabler för att predicera utnyttjande av vård. Tillfredställelse med vården var 
stabil över tid. Metoderna i studie IV var överlag genomförbara. Konklusion: 
Medvetenheten om de psykologiska aspekterna av MS behöver öka bland vårdpersonalen. 
Det finns en möjlighet att öka HRLK genom att minska effekterna av modifierbara faktorer 
och genom att tillgodose behovet av omgivningsfaktorer som syftar till att minska 
funktionshinder. Genom full delaktighet mellan PmMS och deras vårdgivare och genom att 
införa strategier för att koordinera vården mellan olika vårdgivare finns en möjlighet att 
förbättra och effektivisera vården för PmMS. Individuell KBT är genomförbart för PmMS.  
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1 INTRODUCTION 
The starting point for this thesis began in the late 1990 which was the time when the 
Stockholm MS study was conducted, a cross-sectional population-based study of people with 
multiple sclerosis (PwMS) living in Stockholm County. The results from the Stockholm MS 
study gave raise to many further research questions including detailed knowledge of the 
progress of various disabilities in people with PwMS, of potential changes in health related 
quality of life and in use of and patient satisfaction with care in a long-term perspective. It 
was also found that there was a need to increase knowledge of variables important to predict 
changes in these outcomes. In addition, one of the main findings from the Stockholm MS 
study was the high occurrence of PwMS with depressive symptoms. It was also found that 
many PwMS in the Stockholm MS study were dissatisfied with the accessibility to 
psychosocial support/counseling.  
In this thesis I wanted to address the research questions that arose from the Stockholm MS 
study and also to explore the feasibility and effectiveness of different treatment methods for 
alleviating depressive symptoms in PwMS. Therefore, a pilot study exploring the feasibility 
of face-to-face cognitive behavioural therapy (CBT) is included in this thesis.  
2 BACKGROUND 
2.1 MULTIPLE SCLEROSIS 
MS is a neuroinflammatory and neurodegenerative disease, characterised by demyelination 
and axonal degeneration in focal areas of the central nervous system (CNS). Clinical events 
are usually associated with areas of inflammation in the CNS (1, 2).  Even though the cause 
of MS is not yet fully understood, the CNS damage is believed to result from an immune-
mediated process, resulting from an interaction between genes and environmental variables 
such as smoking, infections and a deficit of vitamin D (3). At present, the understanding of 
how environmental variables may impact the immune function in PwMS on a cellular and 
molecular level is emerging (3).  
Even though MS is not considered to be a fatal disease and premature deaths are more likely 
to be due to secondary complications (4), life expectancy is decreased in PwMS compared to 
the general population (5, 6). The clinical course of MS varies from episodes of symptoms 
with total resolution to permanent severe disability. The initial course is often characterised 
by relapses of neurological focal deficits followed by a variable degree of recovery called 
relapsing-remitting MS. About 85 to 90 % of the PwMS initially demonstrate a relapsing-
remitting pattern (2). Eventually, about 10 to 20 years after onset the majority of the PwMS 
enter a progressive phase called secondary progressive MS with an insidious increase in the 
neurological deficits. About 10 to 15% of the PwMS have a primary progressive course 
characterised by a gradually progressive clinical course directly from onset (1). Diagnosis of 
MS is based on established clinical and laboratory criteria (7). 
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There is yet no cure for MS, however a growing body of evidence has shown that the use of 
immunomodulatory treatment reduces the early clinical and sub-clinical disease activity that 
is thought to contribute to long-term disability (8-10). Still, the prognosis at the individual 
level is highly variable and unpredictable and adherence to treatment may be challenging 
(11). Progressive disability will therefore remain the characteristic experience for most 
PwMS over decades. 
MS is recognised worldwide but the incidence and prevalence varies between regions, 
populations and between the sexes. The female to male ratio is reported to be from 2 to 3:1. 
Caucasians are affected more than other racial groups (12) and the prevalence increases with 
increased distance from the equator with parts of northern Europe being high risk areas (13). 
In Europe, the annual incidence estimate of MS varies from 1.28/100 000 to 9.6/100 000 and 
the prevalence from 20/100 000 to 200/100 000 (14). In Sweden, the prevalence of MS is 
reported to be around 189/100 000 which indicates that almost 20 000 people are living with 
MS in Sweden and the female to male ratio is reported to be 2.35:1 (15).  
MS is commonly diagnosed in people who are 20-40 years of age and is the leading cause of 
neurological disability in younger adults. The disease may cause a wide range of symptoms 
including proprioceptive impairment, depression, fatigue, bladder- bowel and sexual 
impairments and cognitive- and motor impairments (16) with a significant impact on health 
related quality of life (HRQL), working ability and ability to fulfil household responsibilities 
(17). MS also threatens personal autonomy and independence, dignity and life planning (18).    
2.2 INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND 
HEALTH 
The International Classification of Functioning, Disability and Health (ICF) (19) is a 
framework which provides a scientific classification system for describing health and 
disability based on a biopsychosocial model of disability and health (20). The ICF comprises 
of two parts with two components respectively, of which the first is ‘Functioning’, a 
comprehensive umbrella term, including the components: body functions/body structures and 
activities and participation. The second part is ‘Contextual factors’, also a comprehensive 
umbrella term, including the components: environmental and personal factors. ‘Disability’ is 
also a comprehensive umbrella term used for the impairment of body function/body 
structures and activity limitations and participation restrictions. The environmental factors 
make up the physical, social and attitudinal environment in which people live and can have a 
hindering or a facilitating impact. Personal factors are the particular background of an 
individual´s life and living, for example age, sex and coping capacity. Functioning and 
contextual factors dynamically interact which each other in a complex relationship, as 
demonstrated in Figure 1.  
In this thesis the ICF was used as a framework but the included variables were not classified 
in detail according to the ICF.  
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Figure 1. The theoretical model of the interactions between health condition and the 
components of the ICF. 
2.2.1 Disability 
In this thesis aspects of disability known to commonly occur in PwMS were studied including 
depression, impaired cognition, limitation in manual dexterity, in walking ability,  in 
activities of daily living (ADL) and restrictions in social/lifestyle activities (21).  
2.2.1.1 Depression 
The diagnosis of major depression is based on the criteria in The Diagnostic and Statistical 
Manual of Mental Disorders, fifth Edition (DSM-V) (22). For a major depression, a person 
must have experienced at least five of the nine symptoms listed in the DSM-V for a minimum 
of two weeks. In clinical practice screening of depression is often managed by a questionnaire 
instead of a diagnostic interview. Some of the defined symptoms occurring on the list of the 
DSM-V as well as on questionnaires might be associated with the neurological changes of 
MS rather than symptoms of depression, such as fatigue, impaired memory and 
concentration. It is important to distinguish whether the symptoms derives from MS or are 
signs of depression.  
Depression is the most common mood disorder in PwMS (23) with an estimated prevalence 
ranging between 20% to 40%  (24-26)  and an estimated lifetime prevalence of about 50% 
(27). Short-term longitudinal studies (up to three years)  (28-30) and one long-term 
longitudinal study (over 10 years) (31), have demonstrated that the occurrence of depression 
is fairly stable over time, however further studies with a long-term longitudinal perspective 
needs to confirm this finding.  
 10 
The aetiology of depression in PwMS is not yet fully understood but is thought to be both a 
complication associated with MS and a symptom of MS (32). It has been proposed that the 
course of depression in PwMS differ from the course in the general population. While the 
general population has episodic periods of the depression, for PwMS it resembles a persistent 
depressive disorder category (22). The differences might partly be explained by studies using 
Magnetic Resonances Imaging (MRI) which have found associations between pathological 
MRI findings and depression in PwMS. These findings strengthen the theory of a disease 
specific aetiology for depression in PwMS (33, 34). However, no clear association has been 
found between depression and disease specific variables such as disease severity, disease 
course or disease duration (24, 35). A short-term longitudinal population-based study found 
an association between increased  disease severity and depressive symptoms (28) while a 
long-term longitudinal study found no such association (31). Further understanding is 
therefore needed about the importance of different variables to predict the outcome of 
depression. 
It has been shown that depressed PwMS do not always receive adequate treatment for 
depression (36) and that they are dissatisfied with the accessibility to psychosocial support 
from the health care system (37). If untreated, depression may lead to increased disability and 
worse HRQL (38). It can also lead to decreased adherence to disease modifying treatment 
(39) as well as an increased the risk for suicide (40).Current treatment for depression in 
PwMS includes antidepressant medication (41), physical exercise (42) and different  
psychological treatment methods (43, 44).  However, further knowledge of effective 
treatment methods for depression in PwMS is needed.  
2.2.1.2 Cognitive impairment 
Cognition can be defined as all mental activities that are associated with thinking, knowing 
and remembering (45). Rather than a global cognitive decline, the cognitive impairment in 
PwMS appears to be characterised of domain-specific deficits. The most commonly impaired 
domains include memory and learning, information processing speed, attention, executive 
functions and visuospatial abilities (46, 47). Cognitive impairment has a negative impact on 
functioning and can disrupt several aspects of daily and social life independently of the 
degree of the physical disability (48). The estimated prevalence of cognitive impairment in 
PwMS ranges from around 40% to 70% (29, 49-52). Cognitive impairment has been reported 
to be present in all stages and severity of the disease (49, 53). Although previous studies have 
found that the proportion of PwMS with cognitive impairment increases over time (54), the 
amount of scientific literature with a long-term  longitudinal perspective is limited and the 
results are inconclusive (55, 56). Further studies with long-term longitudinal perspectives are 
therefore needed  
No clear association has been found between disease related characteristics such as disease 
severity or disease course and cognitive impairment (48, 57). M ale sex, however, has been 
found to be a predictor of cognitive impairment (58) but further insight into the importance of 
different variables to predict cognitive impairment is needed.    
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2.2.1.3 Limitation in manual dexterity 
Limitation in manual dexterity can be defined as the inability to make coordinated hand and 
finger movements in order to grasp and manipulate objects and includes impairments in 
muscular, skeletal, and neurological functions (59). MS is associated with an impaired 
manual dexterity in grasp, lift and grip tasks in foremost dynamic tasks (60-62) and tasks 
such as cutting nails, peeling fruit and buttoning clothes are perceived as difficult (63).  Two 
cross-sectional studies have reported that the prevalence of limitation in manual dexterity 
ranges between 73 to 76% (25, 52). There is sparse literature exploring the limitation in 
manual dexterity over time. One longitudinal  two year study reported that almost 50% of the 
studied sample experienced a clinically meaningful variation in manual dexterity over time 
(29). To explore the long-term occurrence of limitation in manual dexterity, perspective 
longer than two years is needed and further studies are warranted.   
2.2.1.4 Limitation in walking ability 
Limitation in walking ability can be defined in terms of impaired gait patterns such as 
restrictions in walking speed and stride length and prolonged double support phase, all of 
which have been reported in PwMS (64, 65). Limitation in walking ability in terms of 
restrictions in walking distance is often used as a component in the assessment of disease 
severity (66). The prevalence of limitation in walking for PwMS is reported to be high. One 
cross-sectional clinical-based study of the self-perceived walking ability demonstrated that 
about 90% of the PwMS experienced limitation in walking (67). Another cross-sectional 
clinical-based study reported a prevalence of 43% (25) and one population-based study 
reported a prevalence of 92% (52). Differences in results can be attributed to differences in 
MS cohorts under study as well as different methods and instruments used. In addition, the 
use of a walking aid is also common among PwMS. One study reported that 73% of the 
PwMS used a walking aid indoors and that 77% used a walking aid outdoors (67). Walking 
ability is perceived as one of the most valuable activities from the perspective of the PwMS 
(68), and a limitation in walking may increase the risk for falls (67), increase limitation in 
activities of daily living (ADL) and restrict participation in social/lifestyle activities (69). 
Further knowledge of the progress of limitation in walking in a population-based cohort, 
using a long-term longitudinal perspective is needed.  
Restrictions in walking distance is associated with a more severe MS (66), but  to my 
knowledge, no studies of other variables associated with limitation in walking have been 
performed and further studies exploring the importance of different variables to predict 
limitation in walking are needed.  
2.2.1.5 Limitation in activities of daily living 
ADL can be grouped into personal ADL and instrumental ADL. Personal ADL represent 
activities that are performed daily and that are necessary for independent living, such as 
bathing, dressing, eating, transfer from bed to chair, continence and toileting (70). Meanwhile 
instrumental ADL represent activities that are more comprehensive and necessary for the 
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individual in order to live independently in the society, such as household activities and 
transportation (71). Household management, personal care and functional mobility have been 
reported as the ADL that are perceived by the PwMS as the most difficult to perform 
(72).One cross-sectional and one short-term (two years) longitudinal studies have reported 
that about 50% of the PwMS experience limitations in P-ADL (25, 69) and about 70% in I-
ADL (73).  Information on the long-term progress (10 years) of ADL in PwMS is sparse 
although two studies with a follow-up time of 10 years found that in clinical-based cohorts of 
PwMS, limitation in ADL occurs early after diagnosis and that these limitations increases 
over time (74, 75). It is also important to study changes in occurrence of limitation in ADL in 
a population-based cohort.  
In different clinical contexts male sex has been found to be associated with limitations in 
ADL (72, 76) while no associations have been found between limitations in ADL and age, 
disease severity and living arrangement (72). Further studies, in other contexts, are needed to 
explore the importance of different variables to predict limitation in ADL.  
2.2.1.6 Restrictions in social/lifestyle activities 
Social/lifestyle activities are more complex activities compared to ADL and require decision-
making and organisation on the part of the individual. Social/lifestyle activities can include 
working, gardening and going out to eat at a restaurant.   
Cross-sectional studies have demonstrated that about 50 to 75% of the PwMS experience 
restrictions in social/lifestyle activities (25, 69). The scientific literature exploring the long-
term longitudinal progress of restrictions in social/lifestyle activities in PwMS is sparse. One 
study with a follow-up of 10 years found that there was a low level of participation in 
social/lifestyle activities soon after an MS-diagnosis and there was a further decline during 
the course of the disease (74). However, the results were based on a clinical-based cohort of 
PwMS and further studies using a population-based longitudinal perspective are needed. A 
number of studies have found that MS has a devastating impact on working ability (77-79). 
These studies also found that not using immunomodulatory treatment (77), older age (77), 
lower level of education (78), a more severe MS (77, 78) longer disease duration (77, 78) and 
fatigue (78)  were negatively associated with working ability. However, further studies are 
needed to explore the importance of different variables to predict overall  restrictions in 
social/lifestyle activities.   
2.2.1.7 Mortality 
An observational population-based study has reported a decrease in life expectancy of 6 years 
in PwMS (5) and another study reported an almost threefold mortality rate in PwMS 
compared to the general population (6).  MS itself is not considered a fatal disease and 
premature deaths are more likely to be due to secondary complications, such as respiratory or 
infectious diseases. 
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It is possible that the use of immunomodulatory treatment has a positive effect on life 
expectancy (80) and future studies on the long-term effects of disease modifying treatment 
effects is warranted. The influence of age at diagnosis, sex and disease-specific variables on 
mortality in PwMS has been well documented; primary progressive disease course is 
associated with higher mortality from disease onset compared to other disease courses, 
although no differences in mortality between disease courses have been reported from birth to 
time of death (5, 6). Inconclusive results regarding the association between sex and mortality 
are reported (81, 82) and changes in the female to male ratio in MS have been reported as an 
attributional explanation for these inconclusive results (83). However, the association 
between mortality and other personal variables such as coping capacity and aspects of 
impairment such as cognitive impairment and depressive symptoms has not yet been 
explored but would give valuable information of potential risk variables for mortality in 
PwMS and further studies exploring these associations are therefore warranted.  
2.2.2 Contextual factors 
Contextual factors included in this thesis were age, sex and coping capacity, work status and 
level of education. 
2.2.2.1 Sense of coherence 
The salutogenic model sense of coherence (SOC) introduced by Antonovsky describes the 
degree to which a person views the world as meaningful, comprehensive and manageable 
(84) and refers to capacities that facilitate coping with stressors. A stronger SOC implies that 
the person has more resources to cope with stressful situations, such as living with a chronic 
disease such as MS. The SOC is thought to be determined up to the age of 30 and then 
becomes stable over the life course, although it has been reported to change due to a 
traumatic experience (85). Two cross-sectional population-based studies of PwMS reported 
that a weak SOC was associated with depressive symptoms (86) and a lower HRQL (87). A 
two year longitudinal study found that a low to moderate SOC was associated with an 
increased perceived psychological impact of MS (88). Further studies are needed to 
investigate the importance of coping capacity in predicting the outcome of changes in 
different aspects of disability, in mortality rates, in HRQL and in the use of care. 
2.3 HEALTH RELATED QUALITY OF LIFE 
Health is defined by the World Health Organization as ‘a state of complete physical, mental 
and social well-being and not merely the absence of disease or infirmity’ (89). 
 HRQL is a narrower concept than quality of life and includes aspects of quality of life that 
are related to a person’s health (90-92). Measuring HRQL is a method to measure to what 
extent disease and treatment influence important domains of functioning and health (93) and 
has become widely used in clinical trials, effectiveness studies and studies of quality of care 
since measurements of HRQL has been found to be responsive to clinically important 
changes (90). The term ‘self-reported functioning’ is defined as a limited part of HRQL 
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referring to ‘health status’ and functioning (94). Despite the use of different terms, they all 
incorporate the perspective of the individual. There are several methods of measuring HRQL 
in terms of choice of questionnaire, which may be generic (95) (96), or disease specific (97).   
Cross-sectional studies in Europe and Canada have demonstrated that HRQL is negatively 
affected in PwMS compared to the general population (87, 98, 99). Current findings of 
changes in HRQL in a short-time perspective (2-5 years) suggest that although the physical 
dimension of HRQL deteriorates over time (100-102), the psychosocial domain remains 
stable or improves (88, 101, 102). However, whether these findings in HRQL are consistent 
in a long-term perspective (10 years) has not been thoroughly studied and further 
investigations are needed.  
Depressive symptoms (88, 99, 102) and cognitive impairment (88, 99) have frequently been 
shown to predict deterioration in HRQL in studies with a short-term perspective. There are 
also studies which report the impact of a weaker coping capacity (88), a more severe MS 
(99), male sex (99) and lower education (99, 103) to predict deterioration in HRQL in a short-
term perspective. However, to my knowledge it has not yet been determined whether these 
findings are consistent in a long-term perspective (10 years) and further studies are therefore 
needed. 
2.4 CARE 
2.4.1 Definition of care 
Sweden is divided into 20 County Councils of which the Stockholm County Council is 
responsible for the tax financed care in Stockholm County. The use of care services that was 
studied in this thesis includes all the tax financed care for which the Stockholm County is 
responsible, i.e. primary care and hospital outpatient and inpatient care.  
The Departments of Neurology (including Karolinska University Hospital and Danderyd 
Hospital) have the main responsibility for the specialist MS care in Stockholm County. 
Besides MS-specific treatment and rehabilitation provided by the MS-team at the 
Departments of neurology, there are a variety of  other care services involved in the care for 
PwMS, for example within the primary sector or outpatient and inpatient rehabilitation 
centres. 
In addition to the care for which the Stockholm County is responsible, the municipalities in 
Stockholm County are providers of services such as home care and personal assistance, safety 
alarm systems and home adaptions. However, these care services, provided by the 
municipalities, are not included in the definition of care in this thesis.  
2.4.2 Use of care  
Chronic diseases, including MS, offers significant challenges to health care systems (104). 
Previous cross-sectional and short-term (up to three years) studies have found that PwMS use 
a large amount of care (105, 106) however further studies are needed to investigate the use of 
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care in a long-term perspective. A more severe MS has been reported to be associated with a 
higher cost and a higher total amount of care used (105). Short-term longitudinal studies (two 
years) have found that fatigue (107) and depressive symptoms (108) are associated with a 
higher use of care. However, further knowledge is needed on the importance of other 
variables to predict the use of care.     
2.4.3 Guidelines for care 
There are yet no national guidelines for the treatment of MS in Sweden, however in 2014 the 
Swedish Government has launched a national strategy for the prevention and treatment of 
chronic diseases including MS. The aim of the strategy is to develop health care for people 
with chronic diseases and thereby create the prerequisites for a sustainable, effective and 
equal health care. MS is one of the prioritised diagnoses and national guidelines will be 
developed within the next two years (109).  
According to the current clinical guidelines established by the Swedish MS-association (110), 
the specialist MS care should be organised in multi-disciplinary teams including neurologists, 
nurses, physiotherapists, occupational therapists, speech therapists and welfare officers with a 
special interest in MS care and should include MS-specific treatments, symptomatic 
treatments (including spasticity, pain, fatigue and bladder impairment) and rehabilitation. The 
guidelines also state the need for continuous access to these multi-disciplinary teams during 
the MS-trajectory. It is possible that, due to an uneven distribution of neurologists and MS 
specific rehabilitation between rural and urban County Councils in Sweden, the prerequisites 
to follow the guidelines might differ between County Councils in Sweden.     
2.4.4 Patient satisfaction with care 
Patient satisfaction with care is a multidimensional concept which is becoming widely used 
in care services as a measure for the outcome and quality of care, and in that sense, gives 
health care providers information which can be used as the means for improved care. It is 
considered a personal rating of care services and providers (111) but it can also provide 
information on the person, as their rating may be influenced by their expectations, 
preferences and standards (111). A number of studies have demonstrated that PwMS are not 
satisfied with several areas of care, for example; accessibility of care (37, 112) and 
psychosocial support (37, 113, 114); advice on social security matters; and continuity of 
rehabilitation services (114) and participation in planning care (37, 113). Considering that 
MS is a progressive disease and that different health care needs may occur during the MS 
trajectory, it is important to investigate the satisfaction with care in a long-time perspective, 
which has not been done, at least not to my knowledge.   
2.5 COGNITIVE BEHAVIOURAL THERAPY FOR PEOPLE WITH MS AND 
DEPRESSIVE SYMPTOMS 
CBT is a psychological treatment method recommended for people with mild to moderate 
depression by the Swedish National Board of Health and Welfare (115). The CBT model 
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includes behavioural activation, cognitive interventions and depressive symptoms relapse 
prevention (116). Behavioural activation means agreed-to tasks for the patient to perform 
between sessions, such as basic household tasks or participation in a social activity, aimed at 
breaking avoidance behaviours that perpetuate the depressive symptoms. The agreed-to tasks 
are followed up with the help of Socratic questions, aiming at changing negative automatic 
thought processes (116). Usually, a CBT intervention starts with two to three enrolment 
sessions, including informing patients of CBT, assessing of the individual’s ability and 
motivation to assimilate CBT and mapping (conceptualisation and behaviour analysis) for 
goal setting as well as socialisation to the CBT model and psychological education.   
However, the recommended guidelines from the Swedish National Board of Health and 
Welfare are based on studies of people without other chronic physical health problems, so 
CBT may therefore not be appropriate or effective in people with a chronic physical health 
problem (117). The United Kingdom National Institute for Health and Clinical Excellence 
(NICE) (118) recommends CBT for the treatment of depression in people with a chronic 
physical health problem, such as MS, since it offers one of the few ways in which the HRQL 
in this group can be improved. A Cochrane review proposed that CBT might be beneficial for 
PwMS with depressive symptoms, but stated that the evidence is weak due to small study 
populations, different outcome measurements and different types of CBT used (group-, face-
to-face, internet- or telephone-based interventions) and that further studies are warranted 
(119). 
2.6 RATIONALE FOR THE THESIS 
The majority of the PwMS will live with the disease over decades and experience various 
changes and increases in several aspects of disability over time and therefore have various 
needs for different care service over time. For care services to be able to organise and provide 
the appropriate care to meet the needs of the PwMS, it is essential to have detailed knowledge 
of changes in the occurrence of different aspects of disability over the long-term (10 years). A 
deeper understanding of the importance of different variables for predicting these changes is 
also needed. In addition, the patient’s perspective on their health changes, captured by 
measuring HRQL, and patient satisfaction with care services, provides important insights to 
the experience of living with MS and are therefore essential to incorporate when evaluating, 
developing and improving care services for PwMS. In order to create the prerequisites for a 
long-term sustainable effective and equal health care for PwMS, a large knowledge base on 
the use of care as well as predictors on use of care in a long-term perspective is needed. 
Finally, the high prevalence of depressive symptoms among PwMS highlights the urgent 
need for care services to provide effective treatment methods for the depressive symptoms. 
CBT has a potential to decrease depressive symptoms but further knowledge is needed about 
what methods of CBT that is most effective, about the intensity of CBT and about which 
subgroups of PwMS would benefit from this treatment and . To gain this knowledge, a pilot 
feasibility study first needs to be undertaken.          
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3 AIMS 
The overall aim in this thesis was to explore disability, HRQL, the use of care and patient 
satisfaction with care over a 10 year period in a population-based cohort of PwMS in 
Stockholm County. Also, this thesis aimed to explore the importance of different variables in 
predicting the outcome of disability, HRQL and use of care. In addition, the aim was to 
evaluate the feasibility of face-to -face CBT for alleviating depressive symptoms in PwMS. 
Specific aims were: 
I. In a 10 year follow-up of a population-based cohort of PwMS: to explore changes 
in occurrence of disability, and to explore the importance of contextual factors 
and disease-specific variables and depressive symptoms in predicting changes in 
occurance of disability and to explore the importance of personal and disease-
specific variables, depressive symptoms and cognitive impairment in predicting 
mortality rates. 
 
II. In a 10 year follow-up of a population-based cohort of PwMS: to explore changes 
in HRQL, and to explore the importance of contexutal factors, disease severity, 
depressive symptoms and cognitive impairment in predicting changes in  HRQL. 
 
III. In a 10 year follow-up of a population-based cohort of PwMS: to explore the use 
of care, and the importance of contextual factors and disease-specific variables 
and functioning in predicting the use of care, and to explore satisfaction with care 
from the perspective of the PwMS.   
 
IV. To evaluate the feasibility of face-to-face CBT for PwMS with depressive 
symptoms in a single-group pilot feasibility study and the feasibility of methods 
and measurements used and the outcomes of face-to-face CBT on depressive 
symptoms, other disabilities and HRQL before conducting an effectiveness study 
of comparative methods of face-to-face CBT.  
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4 MATERIAL AND METHODS 
Study I, II and III in this thesis has the same methodological approach comprising a 
population-based observational study design with a follow-up time of 10 years. The design of 
study IV comprises a single-group pilot feasibility study.  
STUDY DESIGN 
4.1.1 Observational longitudinal study design 
With an observational longitudinal study design, the researcher collects information about the 
participants and their exposures at baseline, let time pass and then assess the occurrence of 
outcomes. In observational studies, data can be used to explore new ideas about potential 
associations between exposure at baseline and outcomes at follow-up (120, 121). In study I, II 
and III in this thesis, an observational study design was used with a follow-up time of 10 
years. At baseline, data on potential exposures were collected and at the 10-year follow-up, 
data on the outcomes was collected.  In addition, the design also allows studying the change 
in outcome or the change in occurrence of outcome.   
4.1.2 Feasibility study design 
Due to the complexity of evaluating the effectiveness of a psychological intervention, a pilot 
study in which the feasibility of a CBT intervention is studied must be undertaken, in order to 
plan for a study in which the effectiveness of treatment can be studied. A pilot feasibility 
study may answer questions about the feasibility of methods and instruments used and 
hopefully provide answers on how to deal with potential problems (122).  
4.2 PARTICIPANTS AND PROCEDURES 
4.2.1 Study I, II and III 
Study I, II and III is based on a 10-year follow-up of a population-based study of PwMS in 
Stockholm County, Sweden, for which the recruitment process has been described in detail 
previously (52). In brief, the PwMS included at baseline (from September 1999 to September 
2002) were recruited from a temporary data pool consisting of 2129 patients from all hospital 
neurology clinics in Stockholm County, in order to obtain the highest possible population-
based ascertainment, a random sample was drawn, representing 15% (n=321) of the data 
pool. Inclusion criteria were: a definite and informed diagnosis of MS, being a resident in 
Stockholm County and having no diagnosis of other severe neurological or psychiatric illness 
according to the physician. Of the 196 PwMS who fulfilled the inclusion criteria, 166 (85%) 
gave informed consent and agreed to participate. In order to collect data for the 10-year 
follow-up, the same PwMS were identified and those still alive were contacted by post. Data 
collection was performed by home visits at a date 10 years ± 6 months after baseline (from 
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May 2009 to February 2012). Data were obtained using structured face-to-face interviews   
including the same tests and questionnaires, in a standardised order, as was used at baseline. 
In addition, for study I, register-based data including cause and time for death was collected 
from the National Board of Health and Welfare and for study III, register-based data 
including use of care was collected from the Stockholm County Council.   
4.2.2 Study IV 
4.2.2.1 Recruitment of patients 
Recruitment of patients to study IV was conducted at the Department of Neurology, 
Karolinska University Hospital Huddinge. The recruitment process intended to imitate 
clinical praxis for identifying PwMS with depressive symptoms i.e. those PwMS who either 
by telephone or by hospital outpatient visit were in contact with a nurse or a neurologist 
specialized in MS and perceived to be in need of psychological counselling due to depressive 
symptoms were asked to participate. The pilot study aimed at including a strategic sample of 
15 PwMS in order to capture a variation regarding age, sex and disease severity. After giving 
informed consent those PwMS who agreed to participate were contacted by the study 
coordinator to schedule a date for screening and, if included in the study, for baseline face-to-
face data collection. All assessments were performed at the Department of Neurology, 
Karolinska University Hospital, Huddinge.   
4.2.2.2 Inclusion/exclusion criteria 
Inclusion criteria were a definite and informed MS-diagnosis and sub-threshold to moderate 
depressive symptoms comparable to a clinically important level on a validated depression 
scale. Exclusion criteria were having age below 18 years, other severe neurological or 
psychiatric disease according to their physician, antidepressant medical treatment prescribed 
less than three months before inclusion and/or other ongoing psychological treatment. PwMS 
that exhibited depressive symptoms greater than moderate, were re-remitted to their 
neurologist. 
4.2.2.3 Recruitment of therapists 
Three psychologists licensed as psychotherapists and specialized in performing CBT were 
recruited to perform the CBT intervention (they are from now on referred to as therapists). 
The recruitment of therapists was conducted using an advertisement at the website of the 
Swedish Association for Behaviour Therapy. A total of four therapists were interested in 
participating and were interviewed regarding previous experiences in treating PwMS with 
depressive symptoms and the physical accessibility at their clinical practices. One therapist 
withdrew her application and a total of three therapists were recruited.   
4.2.2.4 Intervention 
The CBT intervention was scheduled to comprise 15 to 20 individual face-to-face sessions 
(50 minutes each) with approximately one session/week. The intervention was initiated with 
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three enrolment sessions, including patient information of CBT, motivation to and assessment 
of the individual’s ability to assimilate the CBT intervention. Furthermore, a mapping 
(conceptualization and behavior analysis) for goal setting as well as socialization to the CBT 
model and psychological education were conducted during the enrolment. The CBT included 
behavioural activation, cognitive interventions and depressive symptoms relapse prevention 
(116). Behavioural activation means agreed-to tasks for the PwMS to perform between 
sessions, such as basic household tasks or participation in a social activity, aimed at breaking 
avoidance behaviors that perpetuate the depressive symptoms. The therapists followed up the 
tasks with the help of Socratic questions, aiming at changing negative automatic thought 
processes (116).  
4.2.2.5 Follow-up 
Follow-ups were conducted face-to-face three weeks and three months after completed 
intervention, including the same tests and questionnaires as were used in the baseline data 
collection. 
4.3 TESTS AND QUESTIONNAIRES 
For study I to III, the same tests and questionnaires as in the baseline data collection was 
used. These standardised tests and questionnaires were employed to collect data reflecting 
aspects of disability commonly affected in PwMS. Disease-related variables and contextual 
factors were also collected as were data on HRQL and patient satisfaction with care. As in 
study I, II and III, study IV included instruments reflecting aspects of disability commonly 
affected in PwMS with the addition of variables reflecting feasibility of methods and tests 
and questionnaires used. Table 1 presents the tests and questionnaires used in study I, II, II 
and IV.  
The selection of the tests and questionnaires used was based on recognised reliability and 
validity.   
4.3.1 Disease-specific characteristics 
Disease course and the use of immunomodulatory treatment were determined by the senior 
neurologist using medical notes. Information about concurrent diseases was collected at the 
home-visits.  
4.3.1.1 Disease severity 
4.3.1.1.1 The Expanded Disability Status Scale 
Disease severity was assessed by the data-collectors at the home visits using the Expanded 
Disability Status Scale (EDSS) (66) and was then verified by the senior neurologist. The 
EDSS was developed in order to assess disability in PwMS. The scale ranges from 0 to 10 
were 10 represents death due to MS. The EDSS includes assessment of pyramidal, 
cerebrellar, brain steem, bowel and bladder, visual and mental functions, assessment of 
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walking distance and ambulation. The validity and reliability of the EDSS has been 
questioned (123, 124).  
In study I and IV the EDSS was referred to as “disease severity” and in study II and III as 
“MS disability”.  From here on, the abbreviation “EDSS” will be used when referring to 
disease severity. 
Table 1. Tests and questionnaires used in study I, II, III and IV.   
Tests and questionnaires Study I Study II Study III Study IV 
Questions concerning contextual 
information 
X X X X 
Sense of Coherence Scale X X X X 
Beck Depression Inventory-II X X X X 
Hospital Anxiety Depression Scale    X 
Fatigue Severity Scale    X 
Symbol Digit Modalities Test X X X X 
Mini Mental State Examination  X    
Lindmark Motor Capacity 
Assessment 
   X 
Nine-Hole Peg Test X  X X 
2X5 m walk test X  X  
10 m walk test    X 
The Katz Extended ADL Index X  X X 
The Barthel Index X   X 
Frenchay Activities Index X  X X 
Questionnaire on patient satisfaction 
with care 
  X  
The Sickness Impact Profile  X   
The EuroQol-5D  X  X 
The Multiple Sclerosis Impact Scale    X 
 
4.3.2 Disability  
4.3.2.1 Depressive symptoms 
In clinical practice, screening of depression is often managed by a questionnaire instead of a 
diagnostic interview. The term “depressive symptoms” have been used in this thesis to 
describe what the questionnaire measure since no diagnostic interviews have been employed. 
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4.3.2.1.1 The Beck Depression Inventory-II 
The Beck Depression Inventory II (BDI-II) was used to assess depressive symptoms (125). 
The BDI-II consists of 21 self-rated statements related to depression. The ratings range from 
0 (absent) to 3 (severe), or for one item from 0 (absent) to 2 (severe). The individual is 
instructed to rate each statement and a total score, ranging from 0 to 62 is calculated. The 
inventory is recommended and widely used to asses depressive symptoms in PwMS (36, 126) 
and the validity (70, 127) and reliability (70) are considered good. 
4.3.2.1.2 The Hospital Anxiety and Depression Scale 
The Hospital Anxiety and Depression Scale (HADS) (128) was used to assess anxiety and 
depressive symptoms. The HADS consist of two sub-scales, one related to anxiety and the 
other to depressive symptoms, with a total of 14 self-rated statements. The ratings range from  
0 (absence of a symptom or the presence of positive features) to 3 (maximal presentation of a 
symptom or the absence of positive features). The individual is instructed to rate each 
statement and a total score on each subscale, ranging from 0 to 21 is calculated. Validity 
(129) and reliability (130) is reported to be good. 
4.3.2.2 Fatigue 
4.3.2.2.1 The Fatigue Severity Scale 
The Fatigue Severity Scale (FSS) is a test for assessing perceived level of energy-fatigue. The 
FSS reflects the impact of fatigue on daily functions (131). The FSS includes nine statements 
which are rated on a scale from 1 (strong disagreement) to 7 (strong agreement). The FSS 
score is the mean of all statements. The FSS is found to be valid and reliable (131, 132).  
4.3.2.3 Cognitive impairment 
Aspects of cognitive impairment were assessed by the Symbol Digit Modalities Test (SDMT) 
(133) and the Mini Mental State Examination (MMSE)(134) . 
4.3.2.3.1 The Symbol Digit Modalities Test 
The Symbol Digit Modalities Test (SDMT) (133) is a recommended test for assessing 
attention and processing speed in PwMS (51). The test consists of digits paired with 
geometric symbols. The respondent is asked to replace as many as possible geometric 
symbols on a given time. The SDMT was primarily administrated in a written response but 
for those PwMS unable to write, the SDMT was administrated in a verbal response. The 
SDMT is considered as a reliable test (135) and the validity is reported to be equal to that of 
other screening tools for cognitive impairment in PwMS (136). The SDMT is a 
recommended screening tool for cognitive impairment in PwMS (137).  
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4.3.2.3.2 The Mini Mental State Examination 
The Mini Mental State Examination (MMSE) is a widely used test in clinical settings for 
screening of general cognitive performance (134). Reliability and validity of the MMSE is 
considered good (70).  
4.3.2.4 Impaired global motor capacity 
4.3.2.4.1 The Lindmark Motor Capacity Assessment 
The Lindmark Motor Capacity Assessment (LMCA) (138) was used comprising the sub-
scales for active movements and co-ordination in upper and lower extremities and for balance 
and mobility. The items are mostly scored on a four-point scale from 0 (no function to 4 
(normal function). A summation of the sub-scales, ranging from 0 to 258, is then calculated. 
The LMCA is considered valid and reliable (139, 140).    
4.3.2.5 Limitation in manual dexterity 
4.3.2.5.1 The Nine-Hole Peg Test 
The Nine-Hole Peg Test (NHPT) was used to assess limitation in manual dexterity (141). The 
NHPT consists of a board with nine holes and nine pegs and the instructions for the NHPT is 
to, with one hand at a time, pick up the pegs one-by-one and insert them into the holes on the 
board. The individual is asked to perform the task as fast as possible and the sequence is 
timed with a stopwatch. The NHPT is widely used and is recommended for use in PwMS 
(137) and is considered valid and reliable (141).  
4.3.2.6 Limitation in walking 
4.3.2.6.1 The 10-Meter Walk Test 
For study I and III, the 10-meter walk test was performed with a turn on a five-meter course 
(142). The reason for this was the test was performed in a home environment where a 10-
metre distance may not be available. The individual starts and stops in a standing position and 
is instructed to walk as fast as possible, without risking to fall. Walking aids are allowed and 
noted. A stopwatch was used and the time needed to complete the walk is recorded in 
seconds. The test is considered valid (142) and reliable (143).  
4.3.2.7 Limitations in activities of daily living 
4.3.2.7.1 The Katz Extended ADL Index 
The Katz Extended ADL Index (KI) was used to assess personal and instrumental ADL 
(144). The KI consist of six personal activities including feeding, bathing, dressing, 
continence, toileting and transfer; and of four instrumental activities including: cooking, 
cleaning, transportation and shopping. The items are scored 1 (is dependent) or 2 (is 
independent). The reliability and validity is reported to be sufficient (145). 
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4.3.2.7.2 The Barthel Index 
The Barthel Index (BI) was used to asses personal ADL (146). The BI consists of 10 items 
including: feeding, bathing, grooming, dressing, bowel- and bladder functioning, toilet use, 
transfer, mobility and stairs. The items are scored 0 (is dependent), 5 (need assistance or 
supervision from another person), or 10 (is independent). The BI is considered reliable (147) 
and the validity is reported to be equal to that of other tools of assessing personal ADL (148).     
4.3.2.8 Restrictions in social/lifestyle activities 
4.3.2.8.1 The Frenchay Activities Index 
The Frenchay Activities Index (FAI) was used to assess frequency of social/lifestyle activities 
(149). The FAI consists of 15 items relating to activities that requires initiative and 
organisation on the part of the individual. The scoring is based on the frequency with which 
an item has been performed during the last three or six months from 0 (inactive) to 3 (highly 
active). A total score is then calculated. The FAI was originally developed for use in the 
stroke population but have also been used in studies including other conditions for example 
MS (25, 29, 69). The validity and reliability is reported to be good (149, 150). 
4.3.3 Contextual factors 
Data on age were collected from medical records. Information on level of education and work 
status was collected by interview at the home visits.   
4.3.3.1 Coping capacity 
4.3.3.1.1 Sense of Coherence Scale 
The 13-item Sense of Coherence Scale (SOC) was used to assess coping capacity (84). The 
items are constructed as statements which the individual rates on a Likert scale ranging from 
1 to 7 with anchoring responses for example “never” and “very often”. The SOC-scale is 
considered valid and reliable (84, 151) and is widely used in studies of people with chronic 
diseases including MS (86, 88, 152).  
4.3.4 Health related quality of life 
4.3.4.1 The Sickness Impact Profile 
The Swedish version (153) of the generic Sickness Impact Profile (SIP) (96) comprises 136 
pre-defined items of self-reported functioning, where the respondents answer either “yes” or 
“no” to each item. These items are grouped into 12 categories, belonging to either a physical 
dimension (the SIP Physical dimension) including Body care and movement, Mobility and 
Ambulation, or a psychosocial dimension (the SIP Psychosocial dimension) including 
Emotional behaviour, Social interaction, Alertness behaviour and Communication. The 
remaining five categories Sleep and rest, Home management, Work, Recreation and pastimes 
and Eating are termed independent categories. Scores are calculated using item weighting to 
indicate the relative severity implied by each statement. A total score (the SIP Total) ranging 
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from 0 to 100, where 0 indicates the best possible HRQL and 100 the worst, is then 
calculated. Reliability and validity are considered good (154). The SIP has previously been 
used to assess HRQL in PwMS (87, 155).  
4.3.4.2 The EuroQol-5D 
The generic three level version of the EuroQol 5D consists of the EQ-5D Index and the EQ 
Visual Analog Scale (EQ VAS) (95). The EQ 5D Index comprises five pre-defined 
dimensions: Mobility, Self-care, Usual activities, Pain/discomfort and Anxiety/depression. 
The respondent rates each dimension on a three level scale as having no problem, a moderate 
problem or a severe problem. The answers are then converted to an index value (the EQ 
Index) ranging from 0 (death) to 1 (full health). The EQ VAS records the respondent’s self-
rated health on a 20-centimeter vertical visual analogue scale with end-points ranging from 0 
to 100. The single global question in the EQ VAS asks the individual to label his/her health 
as ‘the worst health you can imagine’ (0) to ‘the best health you can imagine’ (100). The 
reliability and validity has been reported to be acceptable (156). 
4.3.4.3 The Multiple Sclerosis Impact Scale 
The disease-specific Multiple Sclerosis Impact Scale (MSIS-29) (97) comprises of two 
ordinal sub-scales of which one assesses the physical impact of MS and the other the 
psychological impact with a total of 29 items constructed as questions. The physical subscale 
consists of 20 items, and the psychological subscale of nine. The response options are graded 
on a five-point scale ranging from 1 (not at all) to 5 (extremely). The MSIS-29 has proven to 
be valid and reliable for PwMS (157, 158). 
4.3.5 Use of care 
Data on the use of primary care, hospital outpatient care and hospital inpatient care were 
obtained from the computerised register at Stockholm County Council. The register contains 
information regarding all use of care (clinical visits and home visits, telephone consultations 
and inpatient days) with care providers within Stockholm County Council, and detailed 
information including what profession and at which clinic or department the visit concerned. 
Data was obtained on an individual level on all use of care during the study period (10 years). 
4.3.6 Patient satisfaction with care 
A questionnaire on perceived needs and satisfaction with care was used to assess satisfaction 
with care. The questionnaire has previously been used in studies of people with neurological 
disorders (159, 160) including MS (37, 113)  and is based on the taxonomy of Ware (161). 
The taxonomy of Ware includes the dimensions: art of care (engagement/sympathy, kind 
treatment), accessibility, technical quality of care, finances, availability, continuity and 
efficacy/outcome of care. In addition, items relating to patients participation in planning care 
were included. The questionnaire consists of 22 statements which the individual is asked to 
agree or disagree with on a 5-graded scale.   
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4.3.7 Feasibility outcomes  
The pre-specified primary feasibility outcomes of face-to-face CBT for PwMS with sub-
threshold to moderate depressive symptoms included: recruitment procedure, recruitment 
rate, completion rate, potential adverse events and the ability to recruit therapists with the 
formal competence required according to the Swedish National Board of Health and Welfare 
(115). Feasibility of outcome methods including number of completed sessions, number and 
cause of late cancellations (defined as cancellation less than 24 hours before session), 
intensity of treatment, reason for discontinued intervention and modification of treatment was 
collected from a study-protocol used by the therapists who performed the CBT.    
4.4 CATEGORISATION OF VARIABLES 
Recommended cut-offs were used for categorisation of weak/moderate versus strong SOC 
and disability in mood, cognition, manual dexterity, walking speed and social/lifestyle 
activities which are presented in Table 2. Limitation in walking ability was either categorised 
using recommended age- and sex-related norms for walking speed or by the use of walking 
aid.  Age was categorised according to the mean of the sample, and sex into female/male.  
When analysing work status, PwMS ≥65 years of age were excluded since this is the 
customary age for retirement in Sweden. Level of education was dichotomized into primary 
or lower secondary school and high school/university. Disease severity was categorised using 
the EDSS score, into Mild (0 to 3.5), Moderate (4.0 to 5.5), Severe (6.0 to 9.5). Time since 
diagnosis was dichotomized into shorter or longer than 10 years. Type of MS was 
dichotomized into relapsing/remitting and progressive which included secondary progressive 
MS and primary progressive MS. The use of immunomodulatory treatment and the use of 
antidepressant drugs, were categorised as yes or no. Progress in EDSS from baseline to the 
10-year follow-up was dichotomized into no change: ≤1 points change in EDSS from 
baseline to the 10-year follow-up and change: >1 points change. In the absence of a 
recommended cut-off for the KI and the BI, the criterion dependent in one or more items was 
categorised as having a limitation in ADL. Satisfaction with care was dichotomized into 
satisfied (1 to 2 on the scale) or not satisfied (3 to 5 on the scale). Inability to walk 10 metres 
was set to 0 metres/second, inability to perform the NHPT was set to 0 pegs/second and 
inability to perform the SDMT was set to 0.   
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Table 2. Cut-off levels used for below normal performance of coping capacity, for 
depressive symptoms, cognitive impairment, limitation in manual dexterity and in walking 
ability, and restrictions in frequency of social/lifestyle activities. 
1
The cut-off was used in study I, II and III 
2
The cut-off was used in study IV 
4.5 STATISTICAL ANALYSIS 
Descriptive statistics were used in Paper I to IV. A probability value of 0.05 was considered 
statistically significant if nothing else is stated. Statistical analyses were performed in SPSS 
version 20.0 or the SAS® System 9.1.  
Variable Test or questionnaire Cut-off level  
Coping capacity 
  
Sense of Coherence 
Scale 
Norm data from a reference group 
(162). SOC weak: 13-54 points / SOC 
moderate or strong: 55-91 points 
Mood Beck Depression 
Inventory-II 
Depressive symptoms:  13 /  
No depressive symptoms: <13
1
 (36) 
or 
Severe depressive symptoms:  20 / 
Sub-threshold to moderate depressive 
sympoms: 11-19 /  
No depressive symptoms: < 10
2
 (70) 
Cognition 
  
 
  
 
Symbol Digit Modalities 
Test  
 
 
Mini Mental State 
Examination 
Age-related norms (133).  
Impairment:  -1.5 SD from the mean / 
No impairment: <-1.5 SD from the 
mean 
Impairment:  28 / No impairment:  28 
(162) 
Manual dexterity 
  
Nine-Hole Peg Test Norm data from a reference group 
(163).  
Impairment:  0.5 peg /s / 
No impairment: > 0.5 peg/s 
Walking speed 
 
2X5 m walk test Age- and sex-related norms (164).  
Limitation:  -1 SD from average speed/ 
No limitation: < -1 SD from average 
speed   
Frequency of 
social/lifestyle 
activities 
 
Frenchay Activities 
Index 
Age- and sex-related norms (150).  
Restrictions in frequency:  25th 
percentile / Not restrictions in 
frequency:  25th percentile    
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In Study I, the sign test was used for analyses of changes in scores from baseline to the 10-
year follow-up. Statistically significant changes in occurrence of PwMS with disability at 
baseline and at follow-up were analysed with the McNemar test. Generalised Estimating 
Equations (GEE) were conducted to investigate the importance of the independent variables 
(age, sex, coping capacity, level of education, EDSS, disease course, time since diagnosis and 
mood) on an increase in occurrence of PwMS with depressive symptoms (BDI-II), cognitive 
impairment (SDMT), limitation in walking (use of walking aid), limitation in ADL (KI), and 
restrictions in frequency of social/lifestyle activities (FAI) from baseline to the 10-year 
follow-up. Since MS is a progressive disease, time was hypothesised to have a potential to 
interact with the independent variables. Interactions between time and the independent 
variable were therefore controlled for. Independent variables at baseline were included in all 
the models, together with the time variable (0 and 10 year). When the interactions were 
significant the main effects were also retained in the final model irrespective of statistical 
significance. Multicollinearity between the independent variables was controlled for. The 
results are presented as odds ratios (OR) with 95% CI and p values. In case of significant 
interactions, simple effects were presented, i.e. effect of one variable holding the other 
variable fixed. 
In order to analyse the importance of the independent variables (age, sex, time since 
diagnosis, EDSS, disease course, coping capacity, level of education, cognition and mood) on 
mortality rate, univariable Cox regression analyses were performed followed by a 
multivariable Cox regression. The results are presented as hazard ratios (HR) with 95% 
confidence intervals (CI) and p values.   
In Study II the paired t-test was used to analyse changes from baseline to the 10-year follow-
up in scores regarding the SIP Total, the SIP Dimensions (Physical and Psychosocial), the 
EQ-5D Index and the EQ VAS. For analyses of changes in scores regarding the SIP 
Categories the Sign test was used. In order to quantify the change over 10 years in the SIP 
Total, the SIP Dimensions, the EQ-5D Index and the EQ VAS, effect sizes were calculated 
and interpreted using Cohen’s thresholds (165). 
To analyse the importance of the independent variables (age, sex, coping capacity, level of 
education, EDSS, depressive symptoms and cognitive impairment) to predict a change in 
HRQL, as measured with the SIP Total and the EQ VAS, mixed model ANOVAs with 
restricted maximum likelihood estimations (REML) were conducted. Time was hypothesised 
to have a potential to interact with the independent variables. Interactions between time and 
the independent variable were therefore controlled for. Independent variables at baseline were 
included in all the models, together with the time variable (0 and 10 year). Since it was 
theorised that there could be a potential interaction between coping capacity and mood, this 
interaction was also controlled for. Multicollinearity between the independent variables was 
controlled for. To make sure that the EDSS was the most appropriate disease-specific 
variable to be included in the REML containing all independent variables, univariate analyses 
with the Mann Whitney U Test and two REML with only disease-specific variables at 
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baseline (duration of MS, type of MS, use of immunomodulatory treatment and EDSS) as the 
independent variables were first conducted. The final results are presented as estimates of 
effects, described as changes in points from baseline to the 10-year follow-up, with 95% 
confidence intervals (CI) and p values for each final model. Two separate multiple linear 
regression analyses were conducted to ascertain the adjusted coefficient of determination 
(adjusted R2) of the final mixed model ANOVAs with REML regarding the dependent 
variables the SIP Total and the EQ VAS respectively. 
For analyses of differences between survivors and deceased PwMS according to age, EDSS, 
outcome of the SIP Total, the SIP Physical dimension, the SIP Psychosocial dimension and 
the EQ VAS at baseline, the Mann Whitney U Test was used. For differences according to 
gender the Fischers exact test (1-sided) was used.   
In Study III, descriptive statistics were used to analyse use of care (primary care; hospital 
outpatient care and hospital inpatient care) distributed by profession or department from 
baseline to the 10-year follow-up.  In order to analyses the importance of the independent 
variables at baseline (age, sex, coping capacity, level of education, EDSS, use of 
immunomodulatory treatment, type of MS, time since diagnosis, mood, cognitive function, 
manual dexterity, walking ability, ADL, frequency in social/lifestyle activities), and progress 
in EDSS) on the use of care univariable and multivariable linear regression analyses were 
performed. Data on the use of primary care and hospital outpatient care were summarized 
into the dependent variable “total outpatient care” and data on all inpatient care formed the 
dependent variable “inpatient care”. Because of highly skewed distribution of the outcome of 
care, the outcome data was log transformed. For each dependent variable a stepwise analysis 
including all independent variables was performed. The final results of the multivariable 
linear regression analyses are presented as regression coefficient (B) with a 95% confidence 
interval (CI), standardised regression coefficient (Beta) and p value.  
Changes in satisfaction with care in those PwMS who reported a need at both baseline and at 
the 10 year follow-up were analysed using the McNemar test. To explore the use of care for 
PwMS satisfied versus PwMS not satisfied with the efficacy/outcome of primary care, 
hospital outpatient care, inpatient care and inpatient rehabilitation, the Mann Whitney U test 
was used.   
In Study IV, the primary analysis was an intention-to-treat analysis (ITT). For missing data at 
follow-up, the last value was carried forward. The secondary analysis was a completers 
analysis including only participants who completed the CBT. Mean differences in outcomes 
from inclusion to follow-up were calculated. Numbers of PwMS scoring the minimum and 
the maximum possible scores were examined to assess the floor and ceiling effects of the 
measurements. Sample size calculations were conducted for two group t-test. In these 
calculations differences of either five, four, three or two points of the BDI-II from baseline to 
follow-up were tested.    
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5 RESULTS 
5.1 SAMPLE CHARACTERISTICS STUDY I, II AND III 
 Sample characteristics for Study I, II and III are presented together. Of the 166 PwMS 
included at baseline, 32 PwMS were deceased at the 10-year follow-up and 11 declined to 
participate. Consequently, a total of 123 PwMS was included in the 10-year follow-up. Data 
were collected 10 years ± 6 months after baseline data was collected. For Study I and II, four 
PwMS were not able to be interviewed due to severe disability and one had not answered 
most of the questions and was therefore excluded. For study III, one PwMS declined register-
based data to be collected, and one PwMS had moved from Stockholm County and these 
PwMS were therefore excluded. At baseline, mean age was 49 years (SD 11), 86 (70%) of 
the PwMS were female and mean time since diagnosis was 18 years (SD 11). Sample 
characteristics are presented in Table 3.  
Table 3. Number and proportion of people with MS who completed the test at both time 
points and sample characteristics at baseline and at the 10-year follow-up and p value for 
changes in sample characteristic between baseline and the 10-year follow-up, n=123. 
Variable n (%) Baseline 
n (%) 
10-year follow-
up, n (%) 
p value 
Coping capacity 
  SOC Low/Moderate  
  SOC High  
 
110 (89) 
 
14 (13) 
96 (87) 
 
15 (14) 
95 (86) 
 
0.842 
Level of education 
 Primary or lower secondary  
school 
 High school/University 
 
118 (96) 
 
 
28 (23) 
 
90 (77) 
 
27 (23) 
 
91 (77) 
 
0.802 
Working full- or part time
 1
 123 (100) 62 (56) 37 (43) 0.055 
Expanded Disability Status 
Scale 
  Mild 
  Moderate 
  Severe 
 
123 (100) 
 
 
43 (35) 
25 (20) 
55 (45) 
 
 
19 (15) 
23 (19) 
81 (66) 
 
 
<0.001 
0.750 
<0.001 
Type of MS 
  Relapsing/remitting 
  Progressive 
 
123 (100) 
 
58 (47) 
65 (53) 
 
25 (19) 
98 (81) 
 
<0.001 
<0.001 
Immunomodulatory 
treatment 
123 (100) 49 (40) 30 (24) <0.001 
1
Based on PwMS  65 years, n= 109 at inclusion and n= 86 at follow-up 
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Those PwMS who were deceased at the 10-year follow-up were significant older and had a 
more severe MS disability at baseline compared to those PwMS who survived. There was no 
difference regarding sex.   
5.2 STUDY I 
5.2.1 Changes in scores 
There were statistically significant changes (p value <0.001) in median scores in all areas of 
functioning, implying worse functioning, except in mood (p value=0.300). 
5.2.2 Changes in occurrence of disability  
The occurrence of PwMS with disability at baseline and at the 10-year follow-up is presented 
in Table 4. There was an increase in the occurrence of PwMS with disability from baseline to 
follow-up in all areas except in depressive symptoms, cognitive impairment assessed by the 
SDMT, and restrictions in frequency of social/lifestyle activities. At baseline 17 (15%) could 
not walk at all and at follow-up 24 (21%). Seventeen (15%) of the PwMS walked with an aid 
at baseline and 37 (33%) at the follow- up. 
Table 4. Number and occurrence of people with MS categorised as having a disability at 
baseline and at the 10-year follow-up and p values for changes in occurrence with 
disability, n=118. 
Test or questionnaire Baseline 
Disability n (%) 
Follow-up 
Disability n (%) 
p value 
Timed 2x5 m Walk Test 100 (85) 108 (91) 0.027 
Nine Hole Peg Test  65 (55) 77 (65) 0.014 
Mini-Mental State Examination  41 (35) 68 (58) <0.001 
Symbol Digit Modalities Test 49 (42) 48 (41) 1.000 
Beck Depression Inventory II
1
 21
2
 (18) 23
3
 (19) 0.823 
Barthel Index  44 (37) 73 (62) <0.001 
Katz Extended ADL Index  71 (60) 87 (74) 0.002 
Frenchay Activities Index 66 (56) 73 (62) 0.345 
1
113 PwMS completed the test at both baseline and the 10-year follow-up 
2
6 PwMS used antidepressant drugs. 
3
5 PwMS used antidepressant drugs. 
 
5.2.3 Predictors of changes in occurrence of disability 
The final GEE models are presented in Table 5. EDSS at baseline was important to predict an 
increase in occurrence of disability in all assessed areas except depressive symptoms. The 
time variable interacted with ‘time since diagnosis’ for change in occurrence of PwMS with 
limitation in walking, and with the variable ‘age’ for change in occurrence of PwMS who 
were dependent in ADL. Time also interacted with the variables ‘age’ and ‘EDSS’ for 
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changes in occurrence of PwMS with restrictions in social/lifestyle activities.  Time did not 
interact with any independent variable for changes in occurrence of PwMS with cognitive 
impairment or depressive symptoms.   
Table 5. Estimated odds ratios (OR), 95% confidence intervals (CI) and p values for the 
predictive value of the time factor (0 and 10 year) and the independent variables on an 
increase over 10 years in occurrence with depressive symptoms, impaired cognition, 
limitation in walking, limitation in activities of daily living and restrictions in frequency of 
social/lifestyle activities in people with MS according to the final
1
 Generalized Estimating 
Equation models, n=118. 
Dependent 
variable 
Independent variable categorisation  OR (CI) p value 
Depressive 
symptoms
2  
SOC weak 
SOC moderate or strong 
4.05 (1.38-11.85) 
1 (ref) 
0.011 
Impaired 
cognition
3  
 
Male 
Female 
Moderate EDSS  
Mild EDSS  
Severe EDSS  
Mild EDSS  
2.5 (1.1-5.4) 
1 (ref) 
2.9 (1.1-7.9) 
1 (ref) 
3.1 (1.3-7.0) 
1 (ref) 
0.023 
 
0.036 
 
0.008 
Limitation in 
walking
4
 
 
 
Time since diagnosis > 10 years 
Time since diagnosis ≤ 10 years 
Time 10-year follow up 
Baseline 
≤ 10 years since diagnosis / Time: 
10-year follow-up 
Baseline 
> 10 years since diagnosis / Time:  
10-year follow-up 
Baseline 
Moderate EDSS  
Mild EDSS  
Severe EDSS  
Mild EDSS  
1.9 (0.8-4.9) 
1 (ref) 
11.3 (5.0-25.3) 
1 (ref) 
 
30.5 (6.6-140.3) 
1 (ref) 
 
4.2 (2.4-7.2) 
1 (ref) 
6.9 (2.1-22.8) 
1 (ref) 
194.7 (60.1-631.1) 
1 (ref) 
ns 
 
<0.001 
 
 
< 0.001 
 
 
< 0.001 
 
0.002 
 
< 0.001 
 
Limitation in 
activities of daily 
living
5 
 
Age ≥ 51 years  
Age < 51 years 
Time 10-year follow up 
Baseline 
Age < 51 years / Time: 
10-year follow up 
1.4 (0.6-3.2) 
1 (ref) 
3.1 (1.7-5.9) 
1 (ref) 
 
1.8 (0.9-3.6)  
ns 
 
< 0.001 
 
 
ns 
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a
Independent variables and interactions with p values ≤ 0.05 were retained in the final 
models. When the interactions were significant the main effects also were retained in the 
final model irrespective of statistical significance. 
b
Timed 2X5 m Walk Test  
c
Symbol Digit Modalities Test  
d
Beck Depression Inventory 
e
Katz Extended ADL Index 
f
Frenchay Activities Index  
Baseline 
Age  51 years / Time: 
10-year follow-up 
Baseline 
Moderate EDSS  
Mild EDSS  
Severe EDSS  
Mild EDSS  
1 (ref) 
 
5.5 (2.1-14.7) 
1 (ref) 
5.2 (2.1-13.2) 
1 (ref) 
45.9 (13.6-154.3) 
1 (ref) 
 
 
< 0.001 
 
< 0.001 
 
< 0.001 
 
Restrictions in 
frequency of 
social /lifestyle 
activities
6 
 
Age ≥ 51 years  
Age < 51 years 
Time 10-year follow up 
Baseline 
Age < 51 years / Time: 
10-year follow-up 
Baseline 
Age 51 years / Time: 
10-year follow-up 
Baseline  
SOC weak 
SOC moderate or strong 
Moderate EDSS 
Mild EDSS 
Severe EDSS 
Mild EDSS 
Mild EDSS / Time: 
10-year follow-up 
Baseline  
Moderate EDSS / Time: 
10-year follow-up 
Baseline 
Severe EDSS / Time: 
10-year follow-up 
Baseline 
0.9 (0.4-2.2) 
1 (ref) 
1.3 (0.7-2.2) 
1 (ref) 
 
0.6 (0.3-1.3) 
1 (ref) 
 
2.7 (1.1-6.9) 
1 (ref) 
3.4 (1.3-9.2) 
1 (ref) 
3.1 (1.2-8.0) 
1 (ref) 
28.0 (9.4-83.7) 
1 (ref) 
                                     
4.3 (1.5-12.4)    
1 (ref) 
 
1.5 (0.5-4.5) 
1 (ref) 
 
0.3 (0.1-0.7) 
1 (ref) 
ns 
 
ns 
 
 
ns 
 
 
0.033 
 
0.015 
 
0.021 
 
<0.001 
  
 
0.006 
 
 
ns 
 
 
0.004 
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5.2.4 Predictors of mortality 
The univariable Cox regression analyses and the multivariable Cox regression model are 
presented in Table 6. In the multivariable model, older age and depressive symptoms at 
baseline were important variables to predict the outcome of mortality. 
 Table 6. Hazard ratios, 95% confidence intervals (CI) and p values for the association 
between the independent variables on mortality in people with MS over the 10-year period 
according to univariable analyses and the final model of the multivariable Cox regression 
analyses, n=155
1
. 
Independent  
variable 
Variable 
categorisation 
 
Univariable analyses Final model 
  Hazard ratio 
(CI) 
p value  Hazards ratio 
(CI) 
p value 
Age  51 years of age   
< 51 years of age  
3.4 (1.5-7.6) 
1 
0.003 4.6 (1.5-14.4) 
1 
0.009 
Sex 
 
Male 
Female 
1.5 (0.7-3.6) 
1 
0.312  ns 
Sense of 
coherence 
Weak 
Moderate or strong 
1.3 (0.4-4.5) 
1 
0.650  ns 
Education Primary/lower 
secondary school 
High school or 
university 
1.4 (0.7-3.0) 
 
1 
0.349  ns 
Time since 
diagnosis 
> 10 years 
≤ 10 years 
1.9 (0.9-4.1) 
1 
0.078  ns 
Disease 
severity 
EDSS severe 
EDSS moderate 
EDSS mild 
4.0 (1.4-11.6) 
0.9 (0.2-4.9) 
1 
0.009 
0.898 
 
 ns 
Disease 
course 
Progressive  
Relapsing-
remitting 
3.9 (1.5-10.1) 
1 
0.005 3.3 (0.9-11.5) 
1 
0.066 
Cognition Cognitive 
impairment 
No cognitive 
impairment 
1.4 (0.6-3.0) 
 
1 
0.431  ns 
Mood Depressive 
symptoms 
No depressive 
symptoms 
1.8 (0.7-4.8) 
 
1 
0.204 2.7 (1.04-
7.24) 
1 
0.041 
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1
The multivariate Cox regression analyses included all PwMS available at baseline except 
the 11 PwMS who declined to participate in the 10-year follow-up. 
5.3 STUDY II 
5.3.1 Changes in health related quality of life 
5.3.1.1 The Sickness Impact Profile 
Total score, dimensions and categories of the SIP are presented with mean and standard 
deviation (SD) and median and inter-quartile range (IQR) at baseline and at the 10-year 
follow-up in Table 7. Changes with small effect sizes implying worse HRQL at follow-up 
were found in the SIP Total and in the SIP Physical dimension but not in the SIP 
Psychosocial dimension. Changes implying worse HRQL at follow-up were found in the SIP 
categories Body care/movement, and Social interaction and a tendency for worse HRQL was 
found for the category Eating. The change in the category Emotional behavior tended to 
imply better HRQL at follow-up.  
 Table 7. Total score, dimensions and categories of the Sickness Impact Profile with means 
and standard deviations (SD) and median and inter-quartile range (IQR) in people with MS 
at baseline and at the 10-year follow-up, and p-values for changes from baseline to follow-
up, and effect sizes; n =116 
Sickness Impact Profile Mean (SD)   
Baseline Follow-up 
 Median (IQR)  
Baseline   Follow-up 
p-value
 
(Effect size) 
SIP Total 19 (12)   22(13)  20 (10–28)    23 (11–33) 0.001 (0.25) 
SIP Dimensions     
   Physical  21(15)    26(18)  20 (7–34)      25 (11–39) 0.000 (0.33) 
   Psychosocial  14 (12)  15(13)
 
   11 (6–21)     12 (5–21) 0.398 (0.08) 
SIP Categories     
   Sleep and rest   22 (10–35)    22 (10–34) 0.461 
   Emotional behavior   10 (0–25)       0 (0–23) 0.072 
   Body care/movement   16 (4–35)      24 (8–47) 0.000 
   Home management   29 (0–56)      41 (10–68) 0.108 
   Mobility     11 (0–24)    13 (0–25) 0.246 
   Social interaction   9 (0–17)    9 (3–20) 0.042 
   Ambulation   31 (12–40)    34 (23–40)  0.310 
   Alertness behavior   10 (2–30)    13 (0–39)  1.000 
   Communication   9 (0–20)    9 (0–21) 0.253 
   Work   25 (2–70)    24 (0–70) 0.815 
   Recreation/pastime   30 (19–46)    28 (10–48) 0.920 
   Eating       0 (0–5)     0 (0–11) 0.059 
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5.3.1.2 The EuroQol-5D 
 Regarding the EQ-5D Index a change with a small effect size (0.29) from baseline (mean 
0.66 and SD 0.26) to the 10-year follow-up (mean 0.59 and SD 0.30) was found. There was 
no change from baseline (mean 64, SD 22) to the 10-year follow-up (mean 66 SD, 22) in 
HRQL as measured with the EQ VAS. 
5.3.2 Predictors of changes in health related quality of life 
Results from the final mixed model ANOVAs with REML for the SIP Total and the EQ VAS 
respectively, which included the disease-specific variables as independent variables, revealed 
that EDSS at baseline was the only significant variable for predicting a change in HRQL. A 
higher EDSS at baseline predicted a worse HRQL regarding both the SIP Total and the EQ 
VAS. In the final model for the EQ VAS, the independent variable “use of 
immunomodulatory treatment” indicated, but not significantly (p value=0.052), that the use 
of immunomodulatory treatment at baseline predicted a worse HRQL.  
The final mixed model ANOVAs with REML for the SIP Total and the EQ VAS are 
presented in Table 8 and Table 9 respectively. A total of 99 PwMS were included in the 
analyses. The effects on HRQL as measured with the SIP Total revealed that EDSS Severe 
and EDSS Moderate as well as cognitive impairment at baseline predicted worse HRQL at 
the 10-year follow-up, depressive symptoms at baseline tended to predict worse HRQL (p 
value=0.062). The effects on HRQL as measured with the EQ VAS revealed that weak 
coping capacity and depressive symptoms at baseline predicted a worse HRQL, cognitive 
impairment at baseline tended to predict worse HRQL (p value=0.068). No interactions 
between time and the independent variables or between coping capacity and mood were seen 
in either model. The multiple linear regression analyses revealed that the adjusted R
2
 was 
0.378 for the SIP Total and 0.267 for the EQ VAS.  
 
Table 8. Estimates of effects described as change in points of the independent variables and 
the time factor (0 and 10 year) on the Sickness Impact Profile Total with 95% confidence 
intervals, standard errors and p values, for the model with best fit, n=99  
Independent variable Variable  
categorization 
Estimate
1
 
(95% confidence 
interval) 
Standard 
error 
p-
value 
Age Age ≥ 51 years  
Age < 51 years 
2.4 (-1.4 to 6.2) 
reference 
1.9 0.220 
Sex Male 
Female 
1.3 (-2.5 to 5.0) 
reference 
1.9 0.504 
Coping capacity Weak 
Moderate or Strong 
4.6 (-0.8 to 9.9) 
reference 
2.7 0.094 
Education Ground level 1.1 (-3.1 to 5.3) 2.1 0.604 
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High School or University reference 
MS disability EDSS Severe 
EDSS Moderate  
EDSS Mild 
12.4 (8.3 to 16.4) 
6.5 (1.7 to 11.3) 
reference 
2.0 
2.4 
0.000
 
0.008 
Depression Depressive symptoms 
No depressive symptoms 
6.3 (-0.3 to 13.0) 
reference 
3.4 0.062 
Cognition Cognitive impairment 
No cognitive impairment 
7.4 (0.6 to 14.1) 
reference  
2.7 0.033 
Time point  Follow-up  
Baseline 
2.3 (-2.3 to 7.0) 
reference 
2.3 0.315 
1
A positive estimate implies worse health-related quality of life. 
 
Table 9. Estimates of effects described as change in points of the independent variables and 
the time factor (0 and 10 year) on the EQ Visual Analogue Scale with 95% confidence 
intervals, standard errors and p values, for the model with best fit, n=99  
Independent variable Variable  
categorization 
Estimate
1
 
(95% Confidence 
interval) 
Standard 
error 
p-
value 
Age Age ≥ 51 years  
Age < 51 years 
-1.0 (-7.7 to 5.8) 
reference 
3.4 0.778 
Sex Male 
Female 
-4.9 (-11.6 to 1.8) 
reference 
3.4 0.148 
Coping capacity Weak 
Moderate or Strong 
-15.6 (-24.9 to -
6.2) 
reference 
4.7 0.001 
Education Ground level 
High school or 
University 
3.7 (-3.7 to 11.1) 
reference 
3.7 0.326 
MS disability EDSS Severe 
EDSS Moderate  
EDSS Mild 
-5.9 (-13.1 to 1.3) 
-1.3 (-9.8 to 7.2) 
reference 
3.6 
4.3 
0.107
 
0.765 
Depression Depressive symptoms 
No depressive 
symptoms 
-14.2 (-22.5 to -
5.9) 
reference  
4.2 0.001 
Cognition Cognitive impairment 
No cognitive 
impairment 
-5.6 (-11.7 to 0.4) 
reference  
3.1 0.068 
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Time point  Follow-up 
Baseline  
3.3 (-1.3 to 7.9) 
reference 
2.3 0.156 
1
A negative estimate implies worse health-related quality of life. 
 
5.4 STUDY III 
5.4.1 Primary care 
 A total of 23 379 contacts were registered for primary care during the 10-year study period. 
Nurses composed the largest proportion of all use in primary care. Number and proportion of 
users of primary care distributed by health care profession and mean (sd), median (IQR) and 
range of contacts is presented in Table 10. Almost all PwMS had been in contact with 
physicians and nurses during the 10-year study period.    
Table 10.Use of primary care in people with MS during the 10-year period distributed by 
health care profession: number and proportion of users (%), mean (sd), median (IQR) and 
range of contacts, n=121. 
 
 
 
 
 
 
 
 
 
1
Includes professions where less than 5% of the people with MS had been in contact with 
5.4.2 Hospital outpatient care 
A total of 12 706 contacts were registered for hospital outpatient care during the 10-year 
study period. Neurology Departments and Rehabilitation Departments composed two thirds 
of all use of hospital outpatient care. Number and proportion of users of hospital outpatient 
care distributed by department and mean (sd), median (IQR) and range of contacts is 
presented in Table 11. Almost all PwMS had been in contact with Neurology Departments.    
Profession Users, n 
(%) 
Mean (sd) Median 
(IQR) 
Range 
Total 121 (100) 192 (297) 91 (33-210) 1-1884 
Physician 117 (97) 39 (52) 26 (10-43) 1-299 
Nurse 113 (93) 91 (213) 20 (5-93) 1-1428 
Occupational therapist 73 (60) 30 (30) 21 (7-43)  1-140 
Physiotherapist 61 (53) 62 (117) 17 (3-85) 1-789 
Nurse aid 24 (20) 37 (139) 4 (1-15) 1-689 
Orthoptist 15 (12) 12 (11) 11 (2-18) 1-43 
Welfare officer 12 (10) 6 (5) 4 (2-11) 1-16 
Dietician 10 (8) 4 (4) 2 (1-7) 1-14 
Psychologist 7 (6) 10 (7) 10 (4-14) 2-23 
Podiatrist  7 (6) 16 (13) 12 (6-27) 1-40 
Other
1 
15 (12) 6 (8) 2 (2-9) 2-25 
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Table 11. Use of hospital outpatient care in people with MS during the 10-year period 
distributed by department: number and proportion of users, mean (sd), median (IQR) and 
range of contacts, n=121.    
1
Includes departments where less than 5% of the PwMS had been in contact with 
5.4.3 Hospital inpatient care 
A total of 4108 days were registered for hospital inpatient care during the 10-year study 
period. Rehabilitation Departments composed one third of all inpatient care, followed by 
Neurology Departments which composed almost one third of all inpatient care. Number and 
proportion of users of hospital inpatient care distributed department and mean (sd), median 
(IQR) and range of days is presented in Table 12.Three quarters of all PwMS had been 
hospitalized at some point during the study period.   
 
 
Department Users, n 
(%) 
Mean (sd) Median 
(IQR) 
Range 
Total  120 (99) 106 (86) 72 (47-149) 9-543 
Neurology 117 (97)  39 (31) 30 (16-50) 1-160 
Medical service and 
radiology  
103 (85) 5 (4) 4 (2-6) 1-23 
Rehabilitation 92 (76) 42 (66) 18 (5-42) 1-350 
Emergency  83 (69) 5 (6) 3 (1-7) 1-34 
Urology 67 (55) 13 (16) 7 (4-17) 2-59 
Ophthalmology 65 (54) 4 (4) 3 (1-6) 1-15 
Obstetrics and gynecology 63 (52) 5 (5) 4 (1-6) 1-23 
Surgery 61 (50) 7 (14) 3 (1-6) 1-79 
Medicine 56 (46) 5 (7) 3 (1-6) 1-40 
Orthopedics 50 (41) 4 (5) 2 (1-4) 1-30 
Ear, nose and throat 30 (25) 2 (2) 2 (1-3) 1-9 
Dermatology 21 (17) 2 (1) 1 (1-3) 1-4 
Oncology 19 (16) 13 (17) 5 (2-23) 1-56 
Geriatrics 17 (14) 5 (10) 2 (1-4) 1-41 
Infection 13 (11) 5 (8) 1 (1-6) 1-30 
Gastroenterology 11 (9) 7 (12) 2 (1-9) 1-33 
Psychiatry 10 (8) 11 (19) 2 (1-31) 1-40 
Endocrinology 8 (7) 3 (3) 2 (1-3) 1-10 
Other
1
 56 (46) 14 (17) 7 (2-22) 1-71 
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Table 12. Use of inpatient care in people with MS during the 10-year period distributed by 
department: number and proportion of users, mean (sd), median (IQR) and range of inpatient 
days, n=121. 
1
Includes departments where less than 5% of the people with MS had been in contact with 
5.4.4 Predictors of use of care 
For total outpatient care, 65% of the contacts were registered in primary care and 35% were 
registered in hospital outpatient care. The final multivariable regression analysis for the use of 
total outpatient care revealed that a lower coping capacity, use of immunomodulatory 
treatment, limitation in manual dexterity, inability to walk, and limitation in ADL at baseline 
and a progress in EDSS, predicted a higher use of total outpatient care (Table 13). The 
adjusted coefficient of determination for the final multivariable linear regression model was 
0.340. 
 
Table 13. The final multivariable linear regression model for the predictive value of the 
independent variables at baseline, and progress in MS disability, on the use of total outpatient 
care during the 10-year period in people with MS (n=120
1
). 
Department Users, n (%) Mean (sd) Median (IQR) Range 
Total  93 (77)  30 (47) 12 (4-37) 1-302 
Neurology 39 (32) 23 (33) 12 (5-25) 1-167 
Rehabilitation 38 (31) 38 (41) 26 (20-39) 2-222 
Medicine 31 (26) 11 (12) 6 (3-16) 1-49 
Surgery 30 (25) 12 (23) 5 (3-14) 1-132 
Urology 16 (13) 21 (32) 6 (2-33) 1-120 
Orthopedic 15 (12) 7 (8) 5 (2-8) 1-35 
Infection 13 (11) 13 (19) 7 (4-15) 1-71 
Geriatrics 10 (8) 17 (10) 14 (10-26) 6-37 
Obstetrics and 
gynecology 
6 (5) 7 (6) 6 (4-10) 1-18 
Other inpatient care
1
 11 (9) 42 (82) 7 (4-98) 2-189 
Independent 
variable 
Categorisation of 
the independent 
variable 
B 95% CI Beta p value 
Coping capacity  -1.30 -2.74 to 0.20 0.15 0.08 
Immunomodula-
tory treatment  
No  
Yes 
-41.76 
reference 
-98.38 to -1.31 0.17 0.04 
Manual dexterity Impaired   
Not impaired   
43.33 
reference 
-4.29 to 114.26 0.18 0.08 
Walking Cannot walk 
Walk without aid 
105.01 
reference 
23.86 to 
239.06 
0.26 0.01 
Instrumental 
activities of daily 
living  
Limitation 
No limitation 
108.55 
reference 
36.34 to 
218.67 
0.36 0.001 
Progress in MS 
disability   
>1 point change 
≤1 point change 
48.59 
reference 
5.76 to 108.76 0.20 0.02 
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1
One person had no contacts with hospital outpatient care and was excluded from the 
multivariable regression analysis   
The final multivariable regression analysis for the use of inpatient hospital care revealed that 
a weak coping capacity, limitation in manual dexterity and  in personal ADL at baseline and a 
progress in EDSS predicted a higher use of inpatient care (Table 14). The adjusted coefficient 
of determination for the final multivariable model was 0.280.  
Table 14. The final multivariable linear regression model for the predictive value of the 
independent variables at baseline, and progress in MS disability, on the use of inpatient care 
during the 10-year period in people with MS (n=121). 
5.4.5 Patient satisfaction with care 
 Overall, the proportions of PwMS satisfied with different dimensions of care were stable 
over time although the proportion of PwMS who were not satisfied with the accessibility to 
rehabilitation periods; the accessibility to psychosocial support and advice/support of social 
insurance/work rehabilitation; the availability of physicians; and the proportion who had 
participated in planning care ranged between 34-66% at both baseline and at the follow-up.  
There was a significant increase in the proportion of PwMS satisfied with: the accessibility of 
rehabilitation periods and home help service/personal assistance; the availability of nurses; 
and the efficacy of hospital outpatient care. No decrease in satisfaction with care over time 
was seen.  
There was no difference in the use of  care among PwMS satisfied compared to PwMS  not 
satisfied with the efficacy/outcome of primary care (p=0.08), hospital outpatient care 
(p=0.99), hospital inpatient care (p=0.49) or inpatient rehabilitation (p=0.40).   
Independent 
variable 
Categorisation of 
the independent 
variable 
B 95% CI Beta p value 
Coping capacity  Weak 
Moderate/strong 
167.51 
reference 
12.64 to 535.18 0.19 0.03 
Manual dexterity Impaired   
Not impaired   
233.01 
reference 
82.58 to 507.30 0.36 <0.001 
Personal 
activities of daily 
living 
Limitation 
No limitation 
126.60 
reference 
20.80 to 324.61 0.24 0.01 
Progress in MS 
disability  
>1 point change 
≤1 point change 
145.22 
reference 
39.38 to 331.89 0.27 0.002 
  43 
5.5 STUDY IV 
5.5.1 Recruitment, inclusion and follow-up 
Recruitment of PwMS to the pilot study was conducted between June 2011 and January 
2012. Three nurses and two neurologists at the MS-centre participated in the recruitment 
process by identifying PwMS for the screening process. It was found that the clinical 
practices of the therapists were not able to accommodate wheelchairs and PwMS with an 
EDSS ≥ 7.5 could therefore not be included. Twentyone PwMS were screened for inclusion. 
Of these, 15 PwMS met the inclusion criteria and were included. Of the 15 PwMS included, 
nine completed 15-20 sessions of face-to-face CBT and six PwMS discontinued the 
intervention. Of the six PwMS who discontinued the intervention, three were lost to follow-
up. 
5.5.2 Sample characteristics 
Personal- and disease-specific characteristics of the 15 PwMS included in the study as well as 
of the completers and non-completers of intervention at inclusion are presented in Table 15.  
Twelve of the 15 included patients were women, mean age at inclusion was 38 years (SD 7), 
and 11 PwMS were working full- or part-time. For twelve of the PwMS the EDSS was 
assessed as 3.5 or lower. Thirteen PwMS used immunomodulatory treatment and one PwMS 
used antidepressant medical treatment. Five out of nine completers and one out of six non-
completers had university education. The mean time since diagnosis was three years for 
completers and eight years for non-completers.   
Table 15. Personal- and disease-specific characteristics presented for all people with MS 
included, as well as for completers and non-completers of face-to-face cognitive 
behavioural therapy, respectively. 
Variable at inclusion All, 
n=15 
Completers, 
n=9 
Non-completers, 
 n=6 
Female, n 12 8 4 
Mean age, years (sd) 38 (7) 39 (7) 38 (9) 
Living with a partner, n 10 6 4 
Living with children, n 9 7 2 
Level of education, n 
 Primary/Lower secondary level 
 High school 
 University 
 
1 
8 
6 
 
0 
4 
5 
 
1 
4 
1 
Working full- or part- time, n 11 7 4 
Sick-leave full- or part- time, n 6 3 3 
Coping capacity, n 
 Moderate to strong 
 
7 
 
4 
 
3 
Time since diagnosis 
Mean (sd) in years 
 
5 (5)  
 
3 (4) 
 
8 (6)  
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5.5.3 Feasibility outcomes 
The average recruitment rate was two PwMS/month, the completion rate was 60%. Of those 
who did not fulfil the CBT intervention, three had participated in equal to or more than two 
sessions of CBT.   
The average number of CBT sessions was 12/PwMS (range 2-20 sessions) including 
enrolment sessions, and there was a mean of 3 late cancellations/PwMS. The average length 
of the intervention was 25 weeks. The intensity of the intervention varied with an average 
intensity of 0.5 session/week.  
The screening and the data collection procedure at the Department of Neurology, Karolinska 
University Hospital, Huddinge were found to be feasible. No adverse events were reported. 
No instrument demonstrated floor effects although four instruments demonstrated ceiling 
effects: for the LMCA 10 out of 15 scored the maximum score at inclusion; for the BI 13 out 
of 15; for the Katz P-ADL Index 15 out of 15; for Katz I-ADL Index 11 out of 15 scored 
maximum scores at inclusion 
5.5.4 Clinical outcomes 
Mean (sd) and 95% confidence intervals of outcomes of measurements of depressive 
symptoms, anxiety and HRQL at inclusion, three weeks follow-up and three months follow-
up are presented according to ITT and for completers respectively, in Table 16. The ITT 
analyses showed a decrease of the depressive symptoms according to the BDI-II from a mean 
of 17 at inclusion to a mean of nine at three weeks follow-up and eight at three months 
follow-up. The completer analyses demonstrated quite similar results as the ITT analyses 
regarding all measurements used.  
 
 
 
Type of MS, n 
  Relapsing-remitting 
  Secondary progressive 
  Primary progressive 
 
12 
2 
1 
 
7 
1 
1 
 
5 
1 
0 
Disease severity, n 
  EDSS Mild 
  EDSS Moderate   
  EDSS Severe  
 
12 
2 
1 
 
7 
2 
0 
 
5 
0 
1 
Immunomodulatory treatment 13 9 6 
Antidepressant drug, n 1 0 1 
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Table 16. Mean (sd), and 95% confidence interval (CI) of outcomes of the Beck Depression Inventory-II (BDI-II), the 
Hospital Anxiety and Depression Scale (HADS), the Multiple Sclerosis Impact Scale 29 (MSIS-29), EQ VAS and the EQ 
Index at inclusion, three weeks follow-up and three months follow-up, presented for intention-to-treat analyses (ITT) and for 
completers analyses respectively.   
              Inclusion     3-weeks follow-up    3-months follow-up 
Test or questionnaire ITT,  
n=15 
Completers,  
n=9  
ITT,  
n=15  
Completers,  
n=9  
ITT, 
n=15  
Completers,  
n=9  
BDI-II 
 Mean (sd); 95% CI 
 
 17 (3); 15-18  
 
 17 (2); 15-19 
 
 9 (5); 6-12 
 
 7 (4); 4-11 
  
8 (6); 5-11 
 
 7 (4); 4-11 
MSIS-29 
Psychological component  
Mean (sd); 95% CI 
Physical component  
 Mean (sd); 95% CI 
 
  
28 (5); 25-31 
 
43 (15); 34-51 
 
 
28 (6); 23-33 
 
42 (15); 30-53 
 
 
17 (4); 15-23 
 
31 (11); 28- 44 
 
 
17 (4); 13-20 
 
31 (11); 23-39 
 
 
15 (4); 14-22 
 
 31 (11); 28-44 
 
 
15 (5); 12-19 
 
33 (12); 23-41 
EuroQol 5D 
EQ VAS  
 Mean (sd); 95% CI 
EQ Index  
 Mean (sd); 95% CI 
 
 
60 (19); 50-71 
 
0.6 (0.2); 0.5-
0.7 
 
 
 
 57 (22); 40-74 
 
0.6 (0.2); 0.5- 
0.8 
 
 
 71 (15); 62-80 
 
0.7 (0.2); 0.7- 
0.8 
 
 
 73 (16); 61-86 
 
0.8 (0.1); 0.7- 
0.9 
 
  
71 (16); 63-80 
 
0.8 (0.2); 0.7- 
0.8 
 
 
 73 (15); 61-84 
 
0.8 (0.2); 0.7- 
0.9 
 
5.5.5 Estimated sample size calculation 
The sample size estimates per group are summarized in Table 17. With a sample size of 45 
per group, a two group t-test with a significance level of 0.05 and a standard deviation of 5 
will have 80% power to detect a difference in means of three points. 
Table 17. Sample size estimates per group with 80% power and differences in points of the 
Beck Depression Inventory-II (BDI-II) in a two group t-test with equal means with a 
significance level of 0.05 
 
 
 
 
 
 
Mean differences in points 
of the BDI-II 
Effect size Sample size per 
group (n) 
Total sample size 
(attrition 
adjusted) 
5 
4 
1.00 
0.80 
17 
26 
48 
73 
3 0.60 45 126 
2 0.40 100 280 
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6 DISCUSSION 
6.1 MAIN FINDINGS 
There was no change in occurrence of PwMS with cognitive impairment, depressive 
symptoms or restrictions in social/lifestyle activities from baseline to the 10-year follow-up. 
There was an increase in occurrence of PwMS with limitation in manual dexterity, in walking 
ability and in ADL over time. The psychosocial dimension of HRQL was stable over time 
while the physical dimension decreased implying a worse HRQL, however only to a limited 
extent. The use of care over time was extensive and included primary care, hospital outpatient 
and inpatient care and involved many different departments. The EDSS was an important 
variable to predict disability at the 10-year follow-up. Depressive symptoms at baseline was 
an important variable to predict the outcome of a lower HRQL at the 10-year follow-up and 
an increased mortality rate. Low coping capacity at baseline was an important variable to 
predict the outcome of depressive symptoms, a lower HRQL, and a higher use of care. Even 
if patient satisfaction with care was quite stable over time, our findings demonstrate that there 
is room for improvements. Overall, the methods and measurements used in the pilot 
feasibility study of face-to-face CBT were found to be feasible. 
6.1.2 Changes in disability and predictors of disability and mortality 
6.1.2.1 Changes in occurrence of disability 
That the occurrence of depressive symptoms was stable over time needs further investigation 
on an individual level but is in line with previous findings (31, 166). Depressive symptoms in 
PwMS have been found to be undertreated pharmacologically (37) and even though there was 
an increased use of antidepressant drugs, the increase was not among those with depressive 
symptoms. The increased use of antidepressant drugs could instead be explained by an 
increased treatment of, e.g., neurogenic pain.  
Considering the progressive nature of MS, it was a somewhat unexpected finding 
demonstrating that there were no changes in occurrence of PwMS with cognitive impairment 
or restrictions in social/lifestyle activities from baseline to the 10-year follow-up. Previous 
research have demonstrated that cognitive preservation in PwMS may be intact over a short 
period of time, while cognitive deterioration tends to progress over time (49, 55, 56). 
Although the occurrence of PwMS categorised as having a cognitive impairment did not 
change over time, a significant decrease in the raw score of the SDMT was seen. A possible 
explanation for this result can be that the raw score of the SDMT was compared to age-
related norms and the categorisation of impairment was adjusted to age. Since the outcome 
results of the SDMT was dichotomized, we do not know if those PwMS already categorised 
with impaired cognition worsened in their cognitive function over time.  
That the occurrence of restrictions in social/lifestyle activities was stable over time might also 
be an effect of a categorization that was adjusted to age (and gender) related norms (150). It 
could also be explained by an adaptation process to the consequences of living with MS over 
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time, facilitated by contextual factors  such as a moderate or strong SOC and/or facilitating 
environmental variables such as the use of care services which enabled their participation in 
society despite increased disability (19). However, a qualitative study exploring the 
experience of living with MS in the severe stages of the diseases found that from the 
perspective of the PwMS, when EDSS increases, it can be hard or impossible to find new and 
meaningful activities (18).  
More expectedly was the increase in occurrence of PwMS with limitation in manual 
dexterity, walking ability and limitation in ADL. Considering how important it is to manage 
new digital technology such as computers, smart-phones and tablets to participation in our 
society, it is possible that manual dexterity plays an even greater role today compared to 
baseline. This point highlights the importance for manual dexterity to also be thoroughly 
assessed and that studies on the effect of specific interventions that aim to sustain/improve 
manual dexterity should be required. There were significant changes in occurrence of PwMS 
with limitation in both P-ADL and I-ADL, but the change in I-ADL was higher. This has 
been reported previously in a cross-sectional study of PwMS (167) and indicates the 
importance of measuring both P-ADL and I-ADL in order to capture the needs that a PwMS 
requires to manage daily life.  
6.1.2.2 Predictors of changes in occurrence of disability 
Sex and EDSS at baseline did not predict the outcome of depressive symptoms in our study 
(31). In the general population, female sex is a risk factor for depressive symptoms (168). 
Differences in results might be attributional to differences in aetiology between depressive 
symptoms in PwMS compared to the aetiology of depressive symptoms in the general 
population. The aetiology of the depressive symptoms in PwMS needs further investigation 
since the treatment method might differ depending of the cause. That the EDSS at baseline 
was not an important variable to predict a change in occurrence of depressive symptoms over 
time is in accordance with results from other studies (31, 166) and suggests that depressive 
symptoms occur regardless of disease severity. A weak SOC was the only important variable 
to predict an increase in occurrence of PwMS with depressive symptoms. The discriminative 
validity of the SOC scale in relation to measures of depression has though been questioned 
(169, 170) and biological parameters of depression such as saliva cortisol have been found to 
correlate in the same way to SOC (170). However, in the GEE analysis, multicollinearity 
between the SOC and the BDI were controlled for but was not found.  
Despite the criticism against the EDSS regarding validity and reliability (123, 124), it was 
found to predict an increase in occurrence in several areas of disability. This information is 
useful when planning for the overall coming care needs for the individual. 
Time was not a significant independent variable or interacted with any other independent 
variable in the outcomes of cognitive impairment or depressive symptoms, suggesting that 
these impairments occurred early during the MS trajectory and that time did not change the 
occurrence of PwMS with disability in these outcomes.  
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6.1.2.3 Predictors of mortality 
Depressive symptoms at baseline was one predictor for an increased mortality rate over the 
10-year period. Although this result needs to be confirmed in larger populations-based 
studies, it highlights that care professionals need to be aware of the psychological aspects of 
the disease. 
6.1.3 Changes in HRQL and predictors of a change in HRQL 
6.1.3.1 Changes in HRQL 
Our results of a worsened HRQL according to the SIP Total, the SIP Physical dimension and 
the EQ-5D Index over time, could be expected considering the increased EDSS over time, 
however, the effect sizes of these changes were small.  
More surprisingly, however encouraging, were our results demonstrating a stable HRQL 
according to the SIP Psychosocial dimension and the EQ VAS. This finding is consistent 
with previous findings in short-term longitudinal studies of HRQL in PwMS (100-102), but 
seems to apply even in a long-term perspective (10 years). However, there is a possibility for 
individual differences over time (100). Unexpected findings in HRQL in PwMS have been 
explained by the theory of response-shift (100, 102) which refers to changes in internal 
standards, in values or in the conceptualisation of HRQL, catalysed by health-state changes 
(171). The underlying process of response-shift has been described as a way to cope with 
chronic illness (172, 173) and indeed, weak coping capacity was a predictor for worse HRQL 
according to the single global question (EQ VAS). There are studies demonstrating that the 
type of coping strategy is important, at least regarding the psychosocial dimension of HRQL, 
which implies that educating PwMS in coping strategies is a way to increase HRQL (174, 
175) in this group. 
6.1.3.2 Predictors of a change in HRQL 
EDSS (99), depressive symptoms (102, 176, 177) and cognitive impairment (177) have been 
found to predict worse HRQL in PwMS in a short-term perspective, findings that also seems 
to apply to a 10-year  perspective. In the present study, the EDSS predicted worse HRQL 
according to the health profile, but according to the single global question, the EDSS was not 
that important for predicting HRQL. This suggests that the EDSS is not that  important in the 
concept of HRQL according to the PwMS themselves Since depression is a treatable 
condition (115), there is a potential to improve HRQL in PwMS by identifying and initiating 
evidence-based treatment for depressive symptoms (115).  
The prediction models explained almost 40% of the variance in HRQL according to the 
health profile (SIP Total) and almost 30% according to the single global question (EQ VAS). 
Even though the single global question might capture important determinants of HRQL, 
results from a visual analogue scale alone are difficult to interpret in clinic (178) because 
such results do not substantiate the rating of the respondent.  
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6.1.3.3 HRQL in those PwMS who died during the 10-year follow-up 
HRQL according to the health profile (SIP Total) differed significantly at baseline between 
those PwMS who died during the 10-year period and those PwMS who were alive at the 10-
year follow-up, but not according to the single global question (EQ VAS). Those who died 
were also significantly older and had a higher EDSS at baseline compared to those who were 
alive. Previous studies have demonstrated that HRQL is an important predictor for survival 
with cancer and heart failure (179-181). To my knowledge, no such studies have yet been 
conducted with PwMS.  Further studies are needed to explore the associations between 
HRQL and mortality rates of PwMS.  
6.1.4 Use of care, predictors for use of care and patient satisfaction with 
care 
6.1.4.1 Use of care 
There was an extensive use of care over time, including primary care, hospital outpatient and 
inpatient care with many different departments involved. Primary care accounted for the 
majority of all outpatient contacts. However, the use of care was non-normally distributed in 
the study cohort indicating that there was a smaller proportion of PwMS using a majority of 
the care. For those PwMS who use care extensively, coordination between care providers 
might be a challenge. This challenge must be addressed since successful coordination of care 
has a potential to increase health outcomes and reduce the risk for duplicative or contra-
indicated care (182).        
Compared to another study exploring the use of care in PwMS in Sweden (183) our study 
reported a lower use of total outpatient care and number of inpatient days. In an international 
perspective there are studies reporting both a lower and a higher amount of visits to 
neurologists (184, 185) compared to our study, and a higher use of inpatient days at the 
Neurology Departments (185). Differences in results might be attributable to differences in 
study sample, types of data collection, and length of follow-up. These differences as well as 
differences in how care services are organised between countries can make comparisons of 
results a challenge.   
Considering that MS is a neurologic and progressive disease, it was surprising to find that the 
Neurology Departments did not account for more than about one-third of all hospital 
outpatient care. Compared to other European countries the number of neurologist per 
thousand inhabitants in Sweden is low (186). This could explain the relatively low use of 
outpatient care at the Neurology Departments.  
6.1.4.2 Predictors for use of care 
The EDSS at baseline did not predict the outcome of use of care over time and this was a 
somewhat surprising result, which differs from that of another study (105). Rather, a progress 
over time in the EDSS predicted an increased use of care implying that it is a change in 
disability that drives the use of care. Limitation in manual dexterity was an important variable 
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to predict a higher use of both hospital outpatient and inpatient care. It is possible that manual 
dexterity is an even more essential function today compared to 10 years ago considering the 
need to manage a computer, smart-phone or tablet device has almost become a prerequisite in 
order to participate in our society. A limitation in manual dexterity could therefore restrict 
participation in society and induce a need for care i.e. rehabilitation or testing of facilitating 
environmental factors. It is interesting that low coping capacity predicted a an increased use 
of hospital inpatient care since it may point to the importance of self-management programs 
as an essential part of MS care, at least for those PwMS demonstrating a low coping capacity. 
Indeed, self-management programs has emerged as an important part of the care for people 
with chronic diseases, including MS, aiming to learn how to managing aspects of living with 
for example MS, even if further studies is warranted (187).  In PwMS, self-management 
programmes have demonstrated positive effects on managing for example  fatigue (188), to 
increase adherence to immunomodulatory  treatment (189) and to decrease mild 
anxiety/depressive symptoms (190). Potentially, self-management programs could lead to a 
decrease in the need and use of care.  
The prediction models of the use of care explained about one-third of the variance of the use 
of outpatient care and one-quarter of the use of inpatient care. Even though other variables 
not included in the models contribute to the variance of the use of care, the similarity between 
the models strengthens our results.   
6.1.4.3 Patient satisfaction with care 
Even though the high prevalence of depressive symptoms for PwMS is well-known (36) and 
despite the increasing number of studies reporting encouraging results of the effectiveness of 
different psychological treatment methods in reducing the depressive symptoms of PwMS 
(119), the satisfaction with the accessibility to psychosocial support/counselling was low over 
time. The high proportion of PwMS reporting that they had not participated in planning their 
care is noteworthy since a patient-provider partnership has been found to be successful in i.e. 
improving health outcomes (182). The proportion of PwMS satisfied with the accessibility to 
rehabilitation periods increased over time, however about one third of the PwMS was still not 
satisfied. This finding is important since rehabilitation interventions is most important do 
decrease the impact of the disease on impairment, activity limitation and participation 
restriction.    
6.1.5 Feasibility of face-to face CBT 
Even though all PwMS meeting the criteria for depressive symptoms were successfully 
included, the recruitment rate of patients to the study was low. We therefore recommend a 
screening process for a future effectiveness study of comparative methods of face-to-face 
CBT. A screening process has limitations including poorer external validity and significantly 
lower effect sizes (191), however, since PwMS rarely seek treatment for depression a 
screening process would be useful (192). 
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One possible limitation was that no psychiatric confirmed diagnosis of depression was used 
for inclusion. By including PwMS with sub-threshold depressive symptoms there is a risk of 
including PwMS with false-positive answers, however, by increasing the cut-off point to 13 
at the BDI-II, approximately 30% of the PwMS with depressive symptoms might be missed 
(193). To ensure the accuracy of the depressive symptoms we recommend that a certified 
psychologist should be engaged in the analyses of the BDI-II, and that PwMS with sub-
threshold to moderate depressive symptoms should be included but that stability in the 
depressive symptoms should be ensured by two assessments, at screening and before entering 
treatment.   
It was challenging recruiting therapists since there is a lack of the recommended competence 
in Stockholm County, however because of the challenges of treating people with chronic 
diseases it is important to recruit therapists with formal competence (115). The physical 
inaccessibility for wheelchair users at the clinical practices raises a concern about the 
equitability of psychosocial care regardless of physical functioning.   
 Even though no conclusions on the effects of treatment can be drawn from this pilot study, 
the differences in depressive symptoms according to both the BDI-II and the HADS and the 
improvement in HRQL according to the MSIS-29 and the EuroQol-5D should be noted. The 
possibility of modifying CBT to the needs of the patients might be greater with face-to-face 
CBT compared to internet- or telephone CBT and might be an important factor for decreasing 
the depressive symptoms. Also noteworthy is the high number of PwMS demonstrating 
anxiety symptoms at inclusion; therefore, possible changes in anxiety symptoms should be 
examined in an effectiveness study of comparative methods of CBT. 
The ceiling effect noted in the BLMCA, BI and KE, implies that these instruments were not 
useful for this particular sample. If including PwMS with a disease severity over EDSS 7.0 
then we recommend retaining these instruments. Considering that CBT aim to change 
thoughts and behaviours, which can take time, a follow-up time of three months might have 
been too short. We recommend that the follow-up time should be extended to one year.   
Since this pilot study was conducted, two valuable articles on CBT as a treatment method to 
alleviate depressive symptoms in PwMS have been published (126, 194). These studies 
proposed that CBT might be an effective method for alleviating depressive symptoms in 
some subgroups in PwMS but that further knowledge is needed (126, 194) in order to identify 
those PwMS who would benefit from CBT as well as the long-term effects (194). 
Furthermore, that further research is needed in comparative non-pharmacological 
interventions including different approaches (126). With this in mind, we propose a main 
study including two treatment arms, one arm including traditional face-to-face CBT and the 
other including a shorter, low-intensity face-to-face CBT.  
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6.2 METHODOLOGICAL CONSIDERATIONS 
6.2.1 Selection bias 
Selection bias could introduce a systematic error into a study if the probability of being 
selected to the study is related to the independent variables and the outcome (195). When 
using a population-based sample, such as in Study I, II and III in this thesis, the risk for 
selection bias is reduced compared to using a clinical-based cohort (the requirements of the 
population-based case ascertainment have been described previously (52)). However, 15% of 
those PwMS identified at baseline, declined to participate in the baseline study. In addition, at 
the 10-year follow-up, another 11 PwMS declined to participate and 32 PwMS had died. 
Those PwMS who died were older, had a higher EDSS and a lower HRQL at baseline 
compared to those who were alive at the 10-year follow-up. 
6.2.2 Misclassification of the independent variables  
Misclassification of the independent variables is also a systematic error that might occur in a 
study. This might lead to an underestimation of the association between the independent 
variable and the outcome and thereby result in a false negative finding (195).  In Study I, II 
and III most of the independent variables were dichotomized or categorised and might 
therefore be subjected to misclassification. In Study I, II and III the independent variables 
under greatest risk for misclassification would be ‘Age’ and ‘Time since diagnosis’. The cut-
off for the independent variable ‘Age’ was the mean age in the cohort at inclusion and is not 
an established cut-off for “old age”.  The cut-off for ‘Time since diagnoses’ is based on the 
assumption that changes in MS disability occurs frequently during the first 10 years but is not 
an established cut-off. Through using norm data from reference groups regarding cut-offs for 
a low coping capacity (Study I, II and III), impaired cognition (Study II and III), limitation in 
manual dexterity (Study III) and restrictions in frequency of social/lifestyle activities (Study 
III), this might reduce the risk for misclassification.  
6.2.3 Misclassification of outcome 
Misclassification of outcomes can also introduce systematic errors into a study  (195). In 
Study I, all outcome variables were dichotomized and are therefore at risk for 
misclassification. The use of established cut-offs using norm data from reference groups 
regarding cognitive impairment, impaired walking speed and restrictions in frequency of 
social/lifestyle activities and the use of recommended cut-offs for depressive symptoms might 
reduce the risk for misclassification.  
6.2.4 Measurement error 
Measurement errors might occur in a variety of ways and includes both the independent 
variables and the outcomes. Measurement errors include: 
1. Instrumental errors, arising from an imprecis instrument, questionnaire limitations or 
an inaccurate diagnostic test.  
  53 
2. Respondent errors, such as misunderstanding the question or faulty recall. 
3. Observer errors, such as mistakes, imprecise procedures or a misunderstanding of 
procedures.  
4. Data processing errors, including coding, programming and calculating mistakes 
(196).   
To decrease the risk off instrumental errors, the majority of the instruments used were 
choosen because of their overall good psychometric properties, however, not all tests and 
questionnaires were validated or tested for reliability in a MS population. Some instruments 
demonstrated limitations and comprises the EDSS for which the validity and reliability has 
been questioned (123, 124), the SDMT since it does not capture all aspects of cognition 
which might lead to an underestimation of the occurrence of cognitive impairment. In 
addition, the low sensitivity of the MMSE to detect global cognitive impairment in PwMS 
(162) might lead to an underestimation of the proportion of PwMS with cognitive 
impairment. Considering that the FAI was constructed almost 30 years ago, it is possible that 
this instrument does not capture all the aspects of social/lifestyle activities of today. In Study 
II, generic instruments to assess HRQL were used. This might lead to that important issuses 
of HRQL specific for the PMS might not be captured. 
In Study III, the conceptual framework of ‘patient satisfaction’ has been questioned. In 
addition to the framwork proposed by Ware, Carlin et al has proposed a framwork based on 
the assumption that the overall satisfaction with care is a function of the difference between 
the expected care and the actual experience: the greater the difference between the expected 
care and the actual experience, the lower reported patient satisfaction (197). However, there 
are studies demonstrating no or low association between patient satisfaction and the safety 
and outcome of care (198, 199). In a study including people with chronic diseases, 
comprising of ischemic heart disease, chronic obstructive pulmonary disease and diabetes it 
was found that patient satisfaction with care was more strongly associated with the self-
reported ability to cope with the condition than with disease severity. This implies that patient 
education and self-management may lead to improved patient satisfaction with care (198).  In 
addition, Carlin et al concluded in their study of people with chronic diseases that care 
providers who invest in improving their communication with patients will also receive higher 
levels of patient satisfaction, regardless of disease severity (197). Even though the concept of 
satisfaction with care is not yet fully distinguished, it does provide the patient perspective on 
aspects of care services and,  in that sense, can be used to evaluate changes in or to improve  
care organisations and services.  
By using face-to-face data collection in all the studies in this thesis, there is a risk that the 
observer influenced the respondent and thereby resulting in respondent error. However, the 
presence of the observer might also decrease the risk for respondent error since  there was an 
opportunity to explain the questionnaires and to ensure that the questionnaires were filled in 
properly and by the right person. To decrese the risk for observer error the datacollection was 
performed in a standardised manner and the datacollectors were calibrated before the study. 
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The risk of data processing errors can be difficult to detect, so to ensure that these errors were 
as low as possible, all data in this thesis have been validated by two examiners.   
6.2.5 Confounding variables 
A confounding factor is a variable that is associated with both the independent variable and 
the outcome variable and is not a part of the causal chain between the independent variable 
under study and the outcome variable. In observational studies, the control of confounding 
variables will be a major concern (196). There are different statistical strategies to control for 
confounding variables, however these strategies were not applied in the regression models in 
Study I, II and II. Instead, the independent variables were selected based on empirical and or 
theoretical considerations, which could be more important than statistical strategies in 
choosing appropriate confounders (196).  
6.2.6 Regression analyses 
The aims of the regression models in Study I, II and III were not to derive the importance of a 
particular independent variable, but rather to explore the importance of various independent 
variables to predict the future value of the outcome variable. The independent variables 
included in the models were selected by empirical and/or theoretical considerations. A 
stepwise selection procedure was then used to create the final model. However, there is a 
major concern with the stepwise selection procedure in that it tends to overestimate the 
regression coefficient indicating that the performance of the model in predicting future values 
of the outcome will not be as good as we might expect (196). To reduce the risk of an 
overestimated regression coefficient the threshold for retaining an independent variable can 
be adjusted against a lower p value. This in turn might result in omitting an independent 
variable with an actual effect on the outcome.  The risk for omitting an independent variable 
with an actual effect on the outcome is greater in Study I compared to in Study II and III 
since the p value was adjusted to a lower value in the regression analyses in Study I.  
6.2.7 Generalizability 
Generalizability or external validity refers to the extent to which the results can be 
generalised to other populations or situations (196). By using a population-based cohort as in 
Study I, II and III the generalizability increases compared to using a clinical-based cohort. 
However, the prevalence of MS in Sweden is higher today compared to about 10 years ago 
(15, 200) and possible differences  in the male to female ration today compared to 10 years 
ago might affect the generalizability of the results. In addition, since the baseline data 
collection was performed (between September 1999 and September 2002)  there has been a 
huge development not just regarding new and more effective immunomodulatory drugs but 
also in more advanced imaging techniques leading to a greater understanding of the disease 
and a possibility for an earlier diagnosis and thereby an earlier initiation of 
immunomodulatory treatment. There are several new and convincing studies which have 
demonstrated the positive impact of immunomodulatory treatment on MRI parameters (201-
203) clinical outcomes such as relapse rate and disability progression (204-206) and HRQL 
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(207, 208). This is a welcomed development but challenge the generalizability of the results 
from Study I, II and III to new generations of PwMS. Hopefully, the new generations of 
PwMS will experience less impact on functioning and HRQ from the disease. However, since 
there is yet no cure for MS, one characteristic of the disease will still be a progressive 
increase in many areas of disability and an extensive need of different care services as 
demonstrated in Study I and III.  
6.2.8 Methodological considerations in study IV 
The methodological considerations regarding Study IV differs from those of Study I, II and 
III. One of the main methodological limitations in Study IV was the lack of predefined 
stop/go criteria, which would have facilitated the interpretation of the feasibility of an 
effectiveness study. The inclusion procedure attempted to imitate clinical praxis to initiate 
treatment for depressive symptoms but the lack of a psychiatric confirmed diagnosis of 
depression might be considered a limitation and a proposal to diminish this limitation is 
described.  The estimated sample size calculation also has limitations. The small sample size 
might overestimate the clinical effect size (209) and difficulties in assessing a clinically 
important change of the BDI-II in MS-populations has previously been reported (210). These 
limitations are important to consider when estimating the total sample size for an 
effectiveness study of CBT.   
6.3 STUDIES WITHIN THE ICF FRAMEWORK 
When doing research about disability and health among PwMS it is important to include all 
components of the ICF structures since these components interacts with each other and 
produce different health outcomes. The comprehensive protocol used for data collection in all 
studies was constructed in order to include information from all components of the ICF 
structure in order to mirror the multifaceted aetiology of health in PwMS.   
6.4 ETHICAL CONSIDERATIONS 
For some PwMS, the time taken for data collection might have been experienced as too long 
and tiresome.  However, the experience from the baseline data collection in Study I, II and III 
was that the PwMS appreciated the attention as well as the possibility to bring up issues not 
normally dealt with by care professionals. It is possible that for some PwMS, some of the 
tests and questionnaires conducted might have been experienced as discouraging or violating 
integrity. To diminish that risk, the PwMS were clearly informed of the possibility to decline 
participation. When needed, the data collector informed the PwMS about where to turn for 
professional support in different matters.   
6.5 CONCLUSIONS AND CLINICAL IMPLICATIONS 
Even though there is still much to learn about the pathophysiology of MS, the last decades 
have provided new technology and treatment options which improves the prognosis of living 
with MS. However, the results from our studies clearly demonstrate that the vast majority of 
the PwMS will face disability in many areas of functioning leading to impairment, limitations 
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in activity and participation restrictions during the MS trajectory. For a disease without cure, 
symptom management needs to be an essential part of the care of PwMS. The results also 
demonstrate that there is room for improvement regarding the organisation of the 
comprehensive care used by PwMS. The following conclusions could be useful to consider 
when to create the prerequisites for long-term sustainability, effective and equal health for 
PwMS: 
6.5.5 Study I, II and III 
- The stable proportion of PwMS with depressive symptoms over time urge  an 
increased focus on mood disorders in PwMS and the initiation of evidence-based 
treatment when necessary 
- The finding of  increased occurrence of PwMS facing disability over time in many 
concurrent areas demands the use of multidisiplinary teams in order to meet all the 
needs of the PwMS 
- The EDSS could be used as a tool to predict subsequent disability  
- There is a potential to increase HRQL of PwMS by identifying those with depressive 
symptoms and/or cognitive impairment and initiate evidence-based treatment, as well 
as meeting the need for environmental facilitators aimned at reducing disability 
- The comprehensive use of care by the PwMS offers challenges to care coordination 
which demands further investigation 
-  Implementation of person-centred care including self-management programmes, 
could be a strategy to increase efficacy/outcome of care 
6.5.6 Study IV 
- For an effectiveness study of CBT, a screening process for depressive symptoms and 
two comparative intervention arms including traditional face-to-face CBT and low-
intensity face-to-face CBT is recommended. Primary outcomes should include the 
BDI-II and assessment of anxiety symptoms. 
6.6 FUTURE STUDIES 
Results from this thesis demonstrated that the proportion of PwMS with cognitive impairment 
and restrictions in frequency of social/lifestyle activities was stable over time (10 years). 
These results need to be confirmed using other validated instrument when considering that 
the use of SDMT might underestimate the proportion of PwMS with impairment and since 
the validity of the FAI might be questionable.  
The proportion of PwMS with depressive symptoms was also stable over time. This finding 
represents an urgent need for studies that investigate the specific aetiology of depressive 
symptoms of PwMS. There is also a need for a continued focus on which subgroups of 
PwMS that would benefit from different treatment methods for the depressive symptoms i.e. 
different forms of psychological and/or medical treatment.   
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A low coping capacity was identified as an important predictor for the outcome of depressive 
symptoms, a lower psychosocial dimension of HRQL as well as a higher use if hospital 
inpatient care. This variable seems to be important when studying these outcomes and should 
therefore be included in future studies of these outcomes.  
The use of care was studied in Stockholm County, an urban area of Sweden.  To create equal 
care for PwMS in Sweden, there is a need for a longitudinal study investigating the use of 
care in rural areas of Sweden since differences in the organisation of care might lead to 
different uses of care. The results from this thesis demonstrated that the use of care was 
unequally distributed between the PwMS. Identification and further knowledge on this group 
of ‘high-consumers’ of care would be valuable since it is possible that this group has special 
needs regarding the need for example help in order to utilise self-management strategies, 
assitance with coordination of care etc.   
Patient satisfaction with care is becoming an important tool for care providers and 
stakeholders to evaluate the outcomes of different care services (211). However, further 
studies of the underlying concept of satisfaction with care are needed since it has been 
questioned what the concept include and which outcomes it is supposed to measure.   
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